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Abstract 
L- Carnitine is a vitamin like compound synthesised endogenously from the essential 
amino acids methionine and lysine and plays an essential role in the metabolism of 
fatty acids.  Beta-oxidation, the major process by which long chain fatty acids are 
oxidised in mitochondria, depends on carnitine.  In theory, increased carnitine 
availability could increase the ability to transport long chain fatty acids into the 
mitochondria and thus increase their oxidation. 
 
Recent work has however shown that it is unlikely that carnitine supplementation will 
increase fat oxidation and may instead promote carbohydrate metabolism.  
Researched elements have included the role carnitine may play in muscle glycogen 
storage, carnitine as a potential preventative mechanism for clinical populations at 
risk from metabolic disorders and “insulin like” effects observed in carnitine trials. 
 
This study examined the effects of 14 days L-Carnitine L-Tartrate (LC) 
supplementation on blood glucose and insulin response to an oral glucose tolerance 
(OGTT) test and submaximal exercise. Sixteen male participants were recruited and 
assigned to two groups (lean (n=8) and overweight/obese (n=8)). After completing a 
first visit for a submaximal predictive exercise test, participants attended on three 
further occasions, in the morning after an overnight fast, for fasting blood samples 
and 2hr OGTT tests followed by an exercise bout (20 min at 40% of predicted 
VO2peak).  
 
The first test was a familiarisation trial and the final two tests were conducted two 
weeks apart following 14 days of ingestion of placebo (PL, 3g glucose/day) or LC 
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(3g/day) ingested as 2 capsules 3x/day with meals. Blood was drawn at rest and at 15, 
30, 45, 60, 90, and 120 minutes of OGTT and at 10 and 20 min of exercise for 
analysis of glucose and insulin. Data obtained were then used for determination of 
usual insulin sensitivity indices (HOMA-IR, Area Under Curve (AUC) glucose, AUC 
insulin, 1
st
 phase and 2
nd
 phase beta cell function, estimated insulin sensitivity index, 
and estimated metabolic clearance rate).  
 
There was a significant difference between groups for body mass, % fat and BMI with 
no significant difference in age and height.  Mean fasting glucose (5.4(0.2) Placebo 
(PL); 5.5(0.2) L-Carnitine (LC); mmol/L), insulin (13.7(3.5) PL; 13.7(4.2) LC; 
muU/ml) and HOMA-IR (2.6(0.6) PL; 2.7(0.4) LC) were not different between trials, 
and no significant differences were observed between groups prior to 
supplementation. Analysis of the blood glucose response during the OGTT revealed 
no group effect but there was a time effect (P<0.01) and a trial x time interaction 
(p<0.01).  
 
Highest plasma glucose concentration was observed at 30 minutes in both trials but 
was significantly lower (p<0.05) at 30 min in the trial after LC (8.55(0.44) PL; 
7.34(0.36) LC; mmol/L). AUC glucose was not different between trials but AUC 
insulin tended to be higher following LC (5029(889) PL; 5845(1032) LC, p=0.09). 
Estimated 1
st
 phase (281(64) PL; 419(38) LC; muU/ml) and 2
nd
 phase (106(12) PL; 
132(8) LC; muU/ml) beta-cell function were both significantly (p<0.05) greater 
following LC supplementation.  
 
ix 
 
No treatment differences were observed in glucose and insulin response to exercise 
but a trial by group interaction revealed that plasma glucose was lower after 10 
minutes in the lean group (p<0.05) and plasma insulin higher at 20 minutes of 
exercise in the overweight/obese group (p<0.05). No effects of LC supplementation 
were observed on heart rate, VO2 or Respiratory Exchange Ration (RER) during the 
exercise task.  
 
It is concluded that LC appears to induce changes in blood glucose regulation during 
an OGTT, that this may be driven by changes in beta-cell function or in incretin 
levels, with Glucagon Like Peptide-1 (GLP-1) of particular interest, and that this 
response to LC supplementation is not different between lean and overweight/obese 
but may be related to aerobic capacity.  Muscle glycogen levels focusing on an elite 
athlete population are also of interest. 
 
Therefore, further investigation of carnitine action on beta-cell function, incretin and 
muscle glycogen level is warranted. 
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Chapter 1 – Introduction 
 
L- Carnitine (molecular weight 472.49) is a vitamin like compound synthesised 
endogenously from the essential amino acids methionine and lysine and plays an 
essential role in the metabolism of fatty acids.  Beta-oxidation, the major process by 
which long chain fatty acids are oxidised in mitochondria, depends on carnitine (Reda 
et al., 2003; Karlic and Lohninger 2004).  More than 95% of the body’s total carnitine 
store exists within skeletal muscle tissue (Brass, 1995).  The best described function 
of L-carnitine is in its role as a cofactor of Carnitine, acyltransferases transporting 
long-chain fatty acids across the mitochondrial membrane (Karlic and Lohninger, 
2004).  In the absence of L-Carnitine, the inner mitochondrial membrane would be 
impermeable to long-chain fatty acids and fatty acyl-CoA esters.  Thus there are 
reports suggesting that Carnitine supplementation can thus increase the contribution 
of fatty acids to oxidative metabolism (Maughan et al., 2004) and indeed this has been 
shown in normal (Muller et al., 2002) and obese subjects (Wutzke and Lorenz, 2004) 
at rest. 
 
Due to the findings that Carnitine supplementation may not in fact promote fatty acid 
oxidation and may promote carbohydrate metabolism (Hultman et al., 1991; 
Broderick et al. 1992; Millington et al., 1993; Brass et al., 1994; Hawley et al., 1998; 
Karlic and Lohninger, 2004; Maughan et al., 2004, Abramowicz and Galloway, 
2005), Carnitine supplementation may be beneficial to those at risk of developing 
metabolic disorders such as impaired glucose tolerance and type 2 diabetes.   
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Carnitine has been observed to increase non-oxidative glucose disposal during 
hyperinsulinaemic euglycaemic clamps in controls and type II diabetics (Mingrone et 
al., 1999; Giancaterini  et al., 2000) and increase glucose disposal during intravenous 
glucose tolerance testing(De Gaetano  et al., 1999).   Whole body glucose metabolism 
in subjects with type II diabetes is significantly increased after carnitine infusion 
(Capaldo et al., 1991) and similar results were shown to be independent of body 
weight or the degree of insulin resistance (Ferrannini et al., 1988).  In other clinical 
situations such as renal failure (Gunal, 1999) peripheral vascular disease (Brevetti et 
al., 1988) and chronic fatigue syndrome (Plyioplys and Plyioplys, 1997), carnitine has 
been shown to have a positive effect on insulin sensitivity (Gunal, 1999) and exercise 
capacity (Brevetti et al., 1988; Plyioplys and Plyioplys, 1997). 
 
Lean subjects have lower insulin levels whether they are normal, Impaired Glucose 
Tolerant (IGT) IGT or diabetic (Matsumoto et al., 1997) and insulin resistance is a 
major characteristic of obesity and the development of type II diabetes (Stephens et 
al., 2005).  Obesity is a risk factor associated with IGT, dyslipidemia, insulin 
resistanc, hypertension, hyperurecemia and Impaired Fasting Glucose (IFG) (Vega, 
2001) and nutritional interventions including L-Carnitine may play a role in the 
reversal of insulin resistance (Kelly, 2000).  This provides the basis of the study 
supplementing to adult males with a BMI which would class them as being at risk 
from developing such metabolic conditions. 
 
In line with the observations above, a direct insulin like effect of carnitine has also 
been suggested.  A 15% increase in skeletal muscle carnitine content resulted in an 
overnight increase in muscle glycogen content (Stephens et al., 2006) after 
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hyperinsulinemic clamp conditions and Rodgers et al. (2001) observed insulin like 
actions of carnitine on rat cardiac muscle.  This could suggest either a direct effect of 
intracellular carnitine on glycogen synthase activity and therefore rates of glycogen 
synthesis, or effects of extracellular carnitine concentration on insulin sensitivity of 
tissues. 
 
Furthermore, if carnitine has an impact upon insulin sensitivity or insulin release in 
response to an oral glucose load it could result in suppressed mobilization of non-
esterified fatty acids (NEFA; Stumvoll et al., 2000) and thus impact upon substrate 
use during low intensity exercise during which plasma derived NEFA’s are a main 
contributor to skeletal muscle oxidation.  This provides the basis for measuring 
substrate use at low intensity exercise in subjects.  Therefore the aim of the present 
study was to investigate insulin like actions of carnitine on healthy active males and 
sedentary obese subjects. 
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Chapter 2 – Literature Review 
 
2.1 Structure and sources of Carnitine 
Carnitine is a small polar compound that is found is all mammals (figure2.1.1).  L- 
Carnitine is a vitamin like compound synthesised endogenously from the essential 
amino acids methionine and lysine and plays an essential role in the metabolism of 
fatty acids.  More than 95% of the body’s total carnitine store exists within skeletal 
muscle tissue (Brass, 1995; Maughan et al., 2004).  The remaining carnitine is divided 
between extracellular fluids and the liver and kidney (Newsholme and Start, 1973).  
Carnitine homeostasis is maintained through a combination of dietary intake as well 
as endogenous synthesis combined with renal excretion (Borum, 1983).   
 
Carnitine intake in the diet is highly variable and depends largely upon red meat 
intake (Galloway and Broad, 2005).  Dietary intake has been estimated to be between 
20 and 300mg per day for healthy non-vegetarian adults (Rebouche and Chenard, 
1991). And will be in the region of 1-3 mg per day for strict vegetarians (Rebouche et 
al., 1993).  It might be thought that individuals who follow a vegan lifestyle might be 
at increased risk of deficiency, but carnitine can also be synthesized from lysine and 
methionine in the liver and kidney (Maughan et al., 2004) and therefore carnitine is 
classed as a non-essential nutrient (Bremner, 1983). 
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Figure 2.1.1 – Chemical structures of L-Carnitine (molecular weight 472.49), Acetyl-
L-Carnitine and Propionyl-L-Carnitine 
 
Beta-oxidation, the major process by which long chain fatty acids are oxidised in 
mitochondria, depends on carnitine (Reda et al., 2003; Karlic and Lohninger 2004).  
Besides fatty acid oxidation, carnitine may also play a role in maintaining the cellular 
coenzyme A (CoA):acyl-CoA ratio by acting as an acceptor for the acyl group (Jogl et 
al., 2004).  Along with carnitine deficiency, acquired abnormalities in carnitine 
metabolism exist in diverse pathological conditions causing carnitine insufficiency 
6 
 
(e.g. dialysis, diabetes, thyroid disease, obesity and cancer; Reda et al., 2003).  In 
such circumstances, the carnitine insufficiency leaves the subject unable to metabolise 
fat efficiently.  Thus there are reports suggesting that Carnitine supplementation can 
thus increase the contribution of fatty acids to oxidative metabolism (Maughan et al., 
2004).  Again, for this reason, Carnitine is commonly marketed as a “fat burner” by 
sports nutrition manufacturers. 
 
2.2 Role of L-Carnitine 
L- Carnitine is a vitamin like compound synthesised endogenously from the essential 
amino acids methionine and lysine and plays an essential role in the metabolism of 
fatty acids.  Beta-oxidation, the major process by which long chain fatty acids are 
oxidised in mitochondria, depends on carnitine as transport of activated fatty acids 
across the mitochondrial membrane is a carnitine dependant process (Reda et al., 
2003; Karlic and Lohninger 2004).  It has thus been hypothesised that increased 
availability of L-Carnitine will increase the capacity to transport fatty acids into 
mitochondria as well as subsequent oxidation (Hawley et al. 1998).  This beta-
oxidation of fatty acids in the mitochondrial matrix is a major source of cellular 
energy, especially in the heart and muscle.  Besides fatty acid oxidation, carnitine may 
also play a role in maintaining the cellular coenzyme A (CoA):acyl-CoA ratio by 
acting as a receptor for the acyl group (Jogl, et al., 2004; Karlic and Lohninger 2004). 
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Figure 2.2.1 – A schematic diagram of the metabolic roles of carnitine in skeletal 
muscle (Stephens et al., 2007c) 
 
Carnitine’s most important physiological function is the transport of fatty acids across 
the mitochondrial matrix.  Long chain fatty acids are unable to penetrate the inner 
mitochondrial matrix where β–oxidation takes place.  Carnitine acts as the cofactor 
for penetrating the inner mitochondrial membrane.  In the absence of L-Carnitine, the 
inner mitochondrial membrane would be impermeable to long-chain fatty acids and 
fatty acyl-CoA esters.  However, carnitine itself is not the limiting factor in this 
transport process but carnitine palmitoyltransferase I (CPT I) and carnitine 
palmitoyltransferase II (CPT II) activity (McGarry and Brown, 1997). 
 
Control of fatty acid oxidation is vested in the carnitine palmitoyltransferase system, 
which consists of three enzymes: CPT I, CPT II, and carnitine:acylcarnitine 
translocase (CACT).  CPT I exists as three isoforms: CPT IA (liver form), CPT IB 
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(muscle form) and CPT IC (brain form).  No isoforms exist for CPT II or CACT: they 
are the same proteins through out the body (Foster 2004).   
 
In order for the CoA esters of fatty acids to be transported to the inner mitochondrial 
matrix, they must first be converted to carnitine esters (acylcarnitine).  This reaction is 
catalyzed by CPT I which is located in the outer membrane of the mitochondria.  The 
carnitine esters are transported across the inner membrane by the enzyme CACT and 
converted back to CoA esters by CPT II (Jogl, et al., 2004) which is situated on 
matrix side of the inner mitochondrial membrane (Stephens et al., 2007c).  The CoA 
esters then enter the β–oxidation pathway in the mitochondrial matrix.  The carnitine 
used for transport is freed for exchange by CT.  Thus this reaction is fully reversible 
with no need for energy input.  CPT I is considered to be the rate limiting enzyme for 
long-chain fatty acid entry into the mitochondria and oxidation (McGarry and Brown, 
1997; Jeukendrup 2002).   
 
Several regulators of CPT I activity have been proposed, including malonyl-CoA 
concentration, hydrogen ion accumulation in the sarcoplasm, and reduced free 
carnitine availability.  Malonyl-CoA is a potent inhibitor of CPT I and is thus a 
potential candidate for the regulation of fat metabolism.  Malonyl-CoA is formed 
from acetyl-CoA, and malonyl-CoA levels decrease in rodent skeletal muscle from 
rest to moderate intensity exercise, when energy production from fat increases 
(Winder et al., 1989).  It is believed that the resting concentrations of malonyl-CoA 
are sufficiently high to inhibit CPT I, and a decrease in the malonyl-CoA 
concentration would therefore result in a relief of the inhibition of CPT I and 
increased long chain fatty acid transport into the mitochondria (Jeukendrup, 2002).  
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Other factors may be interacting with malonyl-CoA and CPT I in regulating long 
chain fatty acid transport into the mitochondria and the accumulation of hydrogen 
ions has also been proposed. 
 
Starritt et al (2000) studied CPT I activity in isolated mitochondria from resting 
human skeletal muscle and it was found that small changes in pH from 7.0 to 6.8 
inhibited CPT I activity by 50%.  Thus, the relative large decrease in pH during 
intense exercise (>80% VO2max) could explain the reduced fat oxidation rate from 
moderate to high intensity exercise as a result of inhibited CPT I activity. 
 
Another mediator which may be responsible for the decrease in fat oxidation at high 
exercise intensities is decreased free carnitine concentration.  During low intensity 
exercise, the flux through the Pyruvate Dehydroganese (PDH) is lower than the flux 
through the TCA cycle (Constantin-Teodosiu et al., 1991).  This would result in 
minimal acetylation of the carnitine pool.  Relatively low acetylcarnitine 
concentrations and high free carnitine concentrations have been observed (Constantin-
Teodosiu et al., 1991).  With increasing exercise intensity, the flux through PDH may 
increase more rapidly than the flux through the TCA cycle.  This would result in an 
accumulation of acetyl-CoA.  In order to free up the CoA, the acetyl units are bound 
to free carnitine.  This acetylation of the carnitine pool will result in a decrease of the 
free carnitine concentration.  It is possible that the reduced rates of fat oxidation at 
high intensity exercise (Constantin-Teodosiu et al., 1991) are caused by a reduced 
transport of FA into the mitochondria because the availability of free carnitine 
becomes rate limiting (Jeukendrup 2002).  Constantin-Teodosiu et al (1991) showed 
that, at very high intensities (90% VO2max), a large percentage of the carnitine was 
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bound to acetyl-CoA and the concentration of the free carnitine pool was reduced to 
very low levels to support this hypothesis. 
 
 
 
Carnitine relationship with acetyl-CoA also plays a key role as a buffer in the 
mitochondrial matrix by buffering excess acetyl-CoA to form acetylcarnitine 
(Roepstorff et al. 2005; Karlic and Lohninger, 2004).  This has been confirmed in 
contracting frog (Alkonyi et al. 1975) and rat (Carter et al. 1981) skeletal muscle, and 
has also been established in equine and human skeletal muscle during exercise 
(Stephens et al. 2007c).  Acetyl-CoA is an important intermediate in glucose and fatty 
acid metabolism and normally undergoes complete oxidation in the Krebs (TCA) 
cycle in the skeletal muscle.  In some metabolic conditions (e.g. exercise, fasting or 
acute stress) increased pyruvate dehydrogenase (PDH) activity and fatty acid supply 
from activated lipolysis exceed the rate of acetyl-CoA oxidation, which leads to an 
accumulation of acetyl-CoA and of short-chain acyl-CoA esters (Stephens et al. 2005; 
Stephens et al. 2007b; Stephens et al. 2007c; Sahlin, 1990; Constantin-Teodosiu et al. 
1991) which are mainly degradation products of branched chain amino acids (Karlic 
and Lohninger 2004).  These metabolic changes may limit the working capacity of the 
skeletal muscle since the accumulated acetyl-CoA inhibits the activity of the PDH.  
Under these conditions, the acetyl-CoA/CoASH ratio shows a linear correlation with 
the acetylcarnitine/carnitine ratio (Karlic and Lohninger 2004).  The acetyl-
CoA/CoASH ratio is an important regulating factor of the oxidation of pyruvate, α-
ketoglutarate and fatty acids.  All of them depend on the availability of a common 
mitochondrial CoASH pool.  
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During this critical period, carnitine acetyltransferase converts excess acetyl groups 
into acetylcarnitine (Brass and Hoppel, 1978).  Carnitine forms esters with a wide 
range of acyl groups.  The acylation state of the mobile carnitine pool is linked to that 
of the limited and compartmentalized CoA pools, and the carnitine translocase allows 
the transfer of these excess acyl groups as carnitine esters to the cytoplasm.  Hence, 
more CoASH is available in the mitochondrial matrix. 
 
 
Figure 2.2.2 – Potential regulators between carbohydrate and fat metabolism.  
Particular attention is drawn to carnitine’s role buffering acetyl-CoA, resulting in a 
higher availability of CoASH in the mitochondrial matrix (Spriet and Watt, 2003). 
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In essence, the accumulation of acetyl-CoA is due to an enhanced production rate, 
higher than the rate the acetyl-CoA can be used in the TCA cycle such as at exercise 
above the lactate threshold (Wachter et al. 2002).  The removal of this excess acetyl 
CoA in the mitochondria is important as it can potentially inhibit cell function as the 
accumulated acetyl-CoA/COASH inhibits the activity of the pyruvate dehydrogenase 
(Bremner, 1969).  If the skeletal muscle free carnitine pool could be increased, the 
CoASH pool should also rise, potentially resulting in an increased working capacity 
(Wachter et al. 2002) due to enhanced regulation of substrate oxidation in skeletal 
muscle.  This is one such mechanism by which carnitine supplementation could 
potentially enhance regulation / integration of skeletal muscle metabolism. 
 
This acetylation depletes the free carnitine pool however and it has been hypothesised 
that the resulting reduction in the availability of free carnitine to CPT I might be 
limiting to long-chain fatty acid oxidation in human skeletal muscle during exercise 
(McGarry and Brown, 1997; Stephens et al. 2006; Stephens et al. 2007b; Stephens et 
al. 2007c; Roepstorff et al. 2005).  It has been demonstrated that as exercise intensity 
increase to > 70% VO2max, muscle free carnitine falls to ~ 30% (5.6 mmol/kg dm) of 
the total carnitine store and is paralleled by a 35% decrease in the rate of fat oxidation 
(van Loon et al., 2001).  But changes in cytosolic and intramitochondrial carnitine 
content are unknown. 
 
Van Loon et al., (2001) showed that once exercise intensity was increased to 75% 
VO2max, substrate utilisation changed markedly from resting values and intensities 
up to 55% VO2max (there was no measurement between 55% and 75% VO2max).  
The 35% decrease in the rate of fat oxidation, compared with 55% VO2max, was not 
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due to a reduction in the FFA availability and Van Loon et al., (2001) concluded that 
the “glucose-FFA cycle” does not operate during high intensity exercise.  During the 
high intensity exercise, flux through the glycolytic pathway and the PDC reaction 
would greatly exceed flux through the TCA cycle, thereby markedly increasing 
muscle lactate and acetylcarnitine concentrations and reducing free carnitine 
availability.  The study clearly showed marked increases in glycolytic and PDC flux 
with increasing exercise intensity, which were paralleled  by a marked decline in 
muscle free carnitine availability in support of the hypothesis that a decrease in free 
carnitine availability could possibly by directly responsible for the decreased fat 
oxidation.  Whether or not this directly affects CPT I activity is unknown but the 
possibility cannot be excluded that during high intensity exercise the free carnitine 
concentration declines to a value that could limit CPT I activity and reduce long-chain 
fatty acid oxidation (Van Loon et al., 2001). 
 
2.3 Regulation of Carbohydrate and Fat Metabolism 
Fuel metabolism is highly regulated to ensure adequate energy for cellular function.  
In the fasting state, plasma glucose concentration is determined by the rate the 
endogenous glucose is released into the circulation and the rate that glucose is taken 
up by body tissues (Maggs et al., 2007).  In the fasting state, and during physical 
activity, glucagon, secreted from pancreatic α-cells, prevents an abnormal fall in 
plasma glucose by stimulating hepatic glucose production (HGP), while basal rates of 
insulin secretion from pancreatic β-cells act primarily to suppress HGP and prevent an 
abnormal rise in plasma glucose. 
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In the fed state, glucose homeostasis becomes more complex as the gastrointestinal 
tract becomes a second source of (exogenous) glucose.  Marked and rapid changes in 
glucose flux occur as a result of the considerable inflow of meal-derived glucose into 
the circulation.  Insulin secretion rises sharply during the early meal-time period, 
stimulates glucose uptake in peripheral tissue and contributes to the suppression of 
HGP.  Through these mechanisms, insulin in a key factor limiting abnormal 
postprandial glucose excursions (Maggs et al., 2007). 
 
 
Regulation of the activity of the Pyruvate Dehydroganese Complex (PDC)  is an 
important component of glucose homoeostasis (Maggs et al., 2007).  Activation of 
PDC promotes glucose disposal, whereas the suppression of PDC activity is crucial to 
glucose conservation in prolonged starvation, when three-carbon compounds 
(including pyruvate) are required for gluconeogenesis to maintain glycaemia (Sugden 
et al, 2001).  PDC is rendered inactive by phosphorylation by pyruvate dehydrogenase 
kinases (PDKs) and PDC is a target for substrate competition between glucose and 
fatty acids.  This is achieved both via end-product inhibition by the common products 
of glucose and fatty acid metabolism (acetyl-CoA and NADH) and by the opposing 
acute effects of intermediates of the fatty acids and glucose metabolism on the activity 
of the PDKs.  The latter include acute suppression of PDK activity by pyruvate, 
generated via glycolysis or from circulating lactate, and acute activation but the high 
concentration ratios of acetyl-CoA to CoA and of NADH to NAD+ in the 
mitochondria, generated by increased rates of fatty acid β-oxidation (Sugden et al., 
2001). 
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In resting conditions and especially after fasting, fatty acids are the predominant fuel 
used by skeletal muscle.  In contrast to carbohydrate metabolism, which increases as a 
function of the aerobic work rate, fat oxidation is reduced at high intensity exercise.  
Lipolysis in adipose tissue is mostly dependent on the concentrations of hormones 
(epinephrine to stimulate lipolysis and insulin to inhibit lipolysis) and one of the 
important factors determining substrate utilization is the availability of substrates.  It 
was originally thought that that the classical glucose – fatty acid cycle (Randle et al., 
1963) could explain this reciprocal relationship between carbohydrate and fat 
metabolism as shown in figure 2.3.1. 
 
 
Figure 2.3.1 – The glucose – fatty acid cycle or Randle cycle (Randle et al., 1963). 
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Figure 2.3.1 describes potential mechanisms involved in the interaction between fat 
and carbohydrate metabolism.  Fatty acid availability seems to be the dominant factor.  
Increased fatty acid availability would increase acetyl-CoA concentrations: 
accumulation of acetyl-CoA would result in inhibition of PDH: accumulation of 
citrate would inhibit phosphofructokinase (PFK): and accumulation of glucose-6-
phosphate (G6P) would reduce hexokinase activity.  Ultimately, this would inhibit 
carbohydrate metabolism with increasing availability and oxidation of fatty acids.   
 
Recently, specific carrier proteins have been identified in various tissues including 
skeletal muscle (figure 2.2.2) for the transport of fatty acids into the muscle 
(Jeukendrup, 2002).  This was previously viewed as a passive process (Jeukendrup, 
2002; Holloway et al., 2007; Holloway et al., 2008).  In the sarcolemma, two proteins 
have been identified that are involved in the transport of fatty acids across the 
membrane: fatty acid binding protein (FABPpm) and fatty acid translocase protein 
(FAT/CD36) (Holloway et al., 2008).  Considerable evidence has accumulated to 
indicate that FAT/CD36 and FABPpm are important in regulating the uptake of long 
chain fatty acids in cardiac and skeletal muscle (Holloway et al., 2007).  Evidence 
that the transport of fatty acids into the muscle is regulated comes from work showing 
that after fasting, FABPpm is increased in slow-twitch oxidative muscle (Turcotte et 
al., 1997 reviewed by Jeukendrup 2002)  and FABPpm also increases after exercise 
training (Kiens et al., 1997 reviewed by Jeukendrup 2002).  It appears that FAT/CD36 
works in conjunction with CPTI, as together these two proteins predict rates of 
mitochondrial fatty acid oxidation , and FAT/CD36 and CPT I are co-localized in 
mitochondria (Holloway et al., 2007).   
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Whether FABPpm also contributes to regulating mitochondrial long chain fatty acid 
oxidation is not known (Holloway et al., 2007) however it has been shown that that  
plasma membrane FABPpm contributes to regulating fatty acid transport (Stump et 
al., 1993; Zhou et al., 1995 reviewed by Holloway et al., 2007) and there is also 
evidence that FABPpm collaborates with FAT/CD36 to transport long chain fatty 
acids across the plasma membrane (Holloway et al., 2007).  Fatty acid transporters are 
likely to be responsible for most of the transport of fatty acids across the sarcolemma, 
and these transporters can be regulated both acutely and chronically (Jeukendrup 
2002) by altering the rate of long chain fatty acid entry into parenchymal cells 
(Holloway et al., 2007). 
 
Whilst using a combination of exercise protocols in humans and muscle contraction in 
rats, Holloway et al. (2007) showed that unlike FAT/CD36, muscle contraction in rats 
and exercise in humans does not increase mitochondrial FABPpm/mAspAT, while the 
upregulation of this protein in muscle stimulates the rate of fatty acid transport, but 
fails to alter the rate of fatty acid oxidation in isolated mitochondria.  They conclude 
that the FABPpm-induced upregulation of fatty acid oxidation in whole body muscle 
would seem to be solely related to the increased rate of plasmalemmal fatty acid 
transport.   
 
2.4 Impaired Glucose Tolerance / Diabetes 
 
The underlying pathophysiologies of type II diabetes are increased insulin resistance, 
decreased insulin secretion and altered hepatic output of glucose (Maggs et al. 2007).  
Type II diabetes is also associated with β-cell dysfunction as well as insulin resistance 
(Cerf, 2006; Bergman et al., 2002; Cobelli et al., 2007).  Insulin resistance means, in 
its simplest sense, that the ability of insulin to dispose of glucose in the liver, skeletal 
18 
 
muscle, and other peripheral tissues is compromised.  Skeletal muscle is presumed to 
have the greatest impact on whole-body glucose disposal, and hence on insulin 
resistance.  Insulin resistance is usually characterised by higher fasting and post-
glucose loading insulin levels, and a decreased responsiveness of tissue to the insulin 
driven clearance of glucose from the bloodstream. 
 
The pre-diabetic phase known as impaired glucose tolerance (IGT) was first proposed 
by the World Health Organisation (WHO) in 1985.  IGT is defined as a normal fasting 
plasma glucose of <6.0mmol/l and a 2-h post-challenge glucose concentration of 6.0-
6.5 mmol/l (WHO, 1985).  In 1997, the American Diabetes Association suggested 
another category of abnormal glucose metabolism known as impaired fasting glucose 
(IFG) which was defined as a fasting plasma glucose of between 6.1 and 6.9 mmol/dl.  
A third classification of combined IGT/IFG is also available.  Basal endogenous 
glucose output (EGO) is not increased in individuals with IGT and is typically 
considered a later abnormality that only occurs with the onset of type II diabetes.   
 
The categorization of glucose homeostasis by both the American Diabetes 
Association and WHO are related directly to fasting and 2 hour glucose 
concentrations however insulin action and insulin secretion may be related differently 
to fasting and 2hour glucose concentrations (Weyer et al. 1999).  Although having no 
direct measurement of insulin resistance in their study, subjects studied by Annuzzi et 
al. (1985) to examine the relationship between IGT and habitually physical activity 
had similar serum insulin levels in the IGT and control groups despite a substantial 
difference in blood glucose concentrations.  This suggests a reduced insulin sensitivity 
may be present in IGT individuals. 
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Hsieh et al. (2005) sought to explore whether patients classified as IGT, IFG or 
IFG/IGT had differing and more severe defects in insulin resistance and decreased 
insulin secretion.  They found that IGT, IFG and IFG/IGT groups had similar 
increased insulin resistance.  A study involving Pima Indians, a population with a 
high prevalence of glucose intolerance and type II diabetes, showed that IFG and IGT 
had a comparable impairment in insulin release, but those with IFG had a greater 
impairment in early phase insulin secretion and, in addition, increased EGO in 
comparison with individuals with normal glucose homeostasis (Weyer et al. 1999).  
Those with IGT/IFG, even more profound abnormalities in insulin action, insulin 
secretion and EGO were found.  In the groups experiencing IGT, IFG or IGT/IFG the 
decrease in insulin action was accounted for by a lower rate of nonoxidative glucose 
disposal. 
 
It has been shown that lean subjects have lower insulin levels whether they are 
normal, IGT or diabetic (Matsumoto et al. 1997) and insulin resistance is a major 
characteristic of obesity and the development of type 2 diabetes (Stephens et al. 
2005).  Vega (2001) also reviewed that obesity was a risk factor associated with IGT, 
dyslipidemia, insulin resistance, hypertension, hyperurecemia and IFG.  Physical 
training is effective at improving glucose tolerance (Lindgarde et al. 1983; Saltin et 
al. 1979), lifestyle interventions (Rosenberg et al. 2005), including weight loss 
(Chiasson and Rabasa-Lhoret 2004) and increased physical activity, are highly 
effective in preventing or delaying the onset of diabetes in people with IGT (Unwin, 
et al. 2002; Abuissa et al. 2005; Herman et al. 2005) and IGT is associated with low 
habitual physical activity during leisure time and reduced physical fitness (Annuzzi et 
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al. 1985).  Also, exercise combined with weight loss rather than weight loss alone, 
enhances fasting skeletal muscle fat oxidation rates and improves insulin sensitivity in 
obese patients (Goodpaster et al. 1999).  Indeed exercise may be the single most 
important lifestyle factor for both preventing and reversing insulin resistance (Kelly, 
2000). 
 
Improving insulin sensitivity through diet and exercise has been found to decrease the 
incidence of type II diabetes in randomised control trials (Abuissa et al. 2005) and 
targeting those at risk, especially those with IGT or IFG is imperative (Deedwania et 
al. 2005).  Two-thirds of individuals with IGT do not go on to develop overt type II 
diabetes, but are almost at the same increased risk of cardiovascular events as diabetic 
individuals (Kelly, 2000).  Again by targeting these individuals, the focus can be 
attributed to preventative mechanisms.   
 
Nutritional interventions may also be important as a preventative mechanism.  Amino 
acids, including L-carnitine, taurine, and L-arginine may play a role in the reversal of 
insulin resistance (Kelly, 2000).  Anuradha et al. (1999) reported that adding taurine 
to the diet of fructose-fed rats moderated the fructosed induced exaggerated glucose 
levels and hyperinsulinemia and similarly Nakaya et al. (2000) noted a positive effect 
of taurine on insulin sensitivity in a rat model of type II diabetes.  L-arginine (0.52 
mg/kg/min) restored the impaired insulin mediated vasodilation observed in patients 
with obesity and type II diabetes and improved insulin sensitivity in healthy, obese 
and type II diabetic subjects when administered in low doses intravenously (Wascher 
et al., 1997). 
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Stephens and colleagues (2005) conclude that an increase of 2.7 mmol/(kg dm) total 
carnitine content observed could alleviate the decline in fat oxidation rates routinely 
observed at exercise intensities above 75% Wmax.  It is possible that such an increase 
could positively impact upon fat oxidation during exercise in metabolic diseases such 
as obesity and type II diabetes.  Observing this rate of total carnitine content outside a 
lab environment however through oral supplementation has yet proved unachievable 
and Stephens himself acknowledges that maintaining plasma carnitine at a 
supraphysiological concentration (500 µmol/L) by infusing L-carnitine for five hours 
however did not measurably increase muscle total carnitine accumulation (Stephens et 
al. 2005).  Also, any increase in skeletal muscle carnitine content increases fat 
oxidation at rest would have to be investigated, particularly because insulin-resistant 
conditions such as obesity and type 2 diabetes, are associated with an impaired ability 
of skeletal muscle to oxidize fatty acids both at rest and during exercise (Rosenberg et 
al. 2005; Goodpaster et al. 1999; Kelly 2000, Stephens et al. 2006 Stephens et al. 
2007b).  These reports should also be interpreted with caution as in trials where 
Stephens and colleagues have increased muscle carnitine content (Stephens et al. 
2005; Stephens et al. 2006; Stephens et al. 2007a; Stephens et al. 2007b) healthy 
active volunteers have been used as subjects with relatively low subject numbers. 
 
Rodgers et al. (2001) used isolated, perfused rat hearts to compare the effects of a 
physiologic levels of carnitine (50µM) and insulin (75 mU/l[0.5nM]) on glycolysis, 
oxidation of glucose and pyruvate and oxidation of palmitate.  Their results showed 
for the first time that a physiologically relevant concentration of carnitine exerts 
insulin like metabolic effects on the intact heart.  The actions of 50µM carnitine and 
75 mU/L (0.5nM) insulin were very similar on all measurements, although those of 
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carnitine were approximately 25-30% lower in magnitute.  Carnitine mimicked 
insulin’s actions on glycolysis, glucose oxidation, pyruvate oxidation, and palmitate 
oxidation.  Both the timing and the duration of the response were also similar.  Also, 
the augmentation of glycolysis by each agent more than accounted for the attendant 
increase in glucose oxidation. 
 
However this glycolysis driven glucose oxidation may explain the individual actions 
of insulin or carnitine, it may not account for their effects in combination (Rodgers et 
al., 2001).  Rodgers and colleagues observed further stimulation of glucose oxidation 
when combining carnitine and insulin however this was not accompanied by an 
additional enhancement of glycolysis.  Although no solid mechanisms are proposed, 
the insulin like effects of a physiologic concentration of carnitine on cardiac 
metabolism holds potential therapeutic significance of carnitine supplementation in 
clinical diabetes.  Also, by targeting obese and inactive populations, L-carnitine may 
help to reduce insulin resistance before clinical stages such as IGT have been reached. 
 
2.5 β -Cell Function 
 
The β-cell is metabolically distinct from almost all other mammalian cell types in 
several respects: it can utilize glucose in the physiologically relevant range (2-20 mM) 
as it expresses a combination of GLUT-2 and glucokinase; it possesses low lactate 
dehydrogenase and plasma membrane mono-carboxylate pyruvate / lactate transporter 
activity and correspondingly high activity in the mitochondrial malate / aspartate 
shuttle, so ensuring mitochondrial oxidation of NADH; it has high activity of both 
pyruvate carboxylase ensuring the anaplerotic and oxidative metabolism of glucose / 
pyruvate can co-exist.  All of these adaptations are geared to enhancing mitochondrial 
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TCA cycle activity, oxidative phosphorylation and efficient ATP production 
(Newsholme et al., 2005).  An important aspect of β-cell function is the ability to 
increase insulin release in appropriate amount and time course to cope with acute 
changes in plasma glucose concentration (Ferrannini et al., 2004). 
 
Type II diabetes is also associated with β-cell dysfunction as well as insulin resistance 
(Cerf, 2006).  The relative contribution in the alterations in insulin sensitivity versus 
β-cell function in the development of diabetes remains unclear, it is clear that 
reductions in both processes have already occurred by the time hyperglycemia 
develops (Chiasson and Rabasa-Lhoret 2004).  Most of the pancreatic transcription 
factors that are important for β-cell maintenance are found in other islet cell types and 
may also reside in pancreatic ducts.  In the mature pancreas, transcription factors play 
a role in achieving glucose homeostasis by regulating the expression of key genes 
involved in maintaining the β-cell phenotype, most notably the insulin gene.  
Improving our knowledge of these important transcription factors, establishing their 
hierarchy, finding novel transcription factors, and ultimately regulating their 
expression to ensure glucose homeostasis may be the key to prevent β-cell 
dysfunction (Cerf, 2006). 
 
Defective function of the pancreatic β-cells is now accepted to be a hallmark of type I 
and type II diabetes although the importance of the β-cell in type I diabetes has long 
been accepted (Bergman et al., 2002).  Type II diabetes is often a “2-hit” 
phenomenon, in which insulin resistance is accompanied by a β-cell defect preventing 
compensatory upregulation of insulin secretion.  It has been postulated (Bergman et 
al., 2002) that increased insulin resistance should upregulate β-cell sensitivity, 
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whereas decreased insulin resistance would downregulate β-cell sensitivity.  It is also 
reasonable to assume that β-cells would suffer from a reduced ability to upregulate 
insulin secretion in the face of insulin resistance when they are defective.  It is only 
later in life when insulin resistance becomes profound that that the presence of any β-
cell defect would become obvious.  Careful assessment of β-cell response may 
however allow for early prediction of those who will eventually show type II diabetes.  
The compensatory ability of the β-cell is the single physiological process that protects 
well-fed individuals from type II diabetes.   
 
It is possible that the insulin sensitivity of muscle, liver and adipose tissue may 
themselves play a regulatory role and are sensitized by insulin to ultimately reduce the 
hyperinsulinemia necessary to keep glycemia within normal ranges.  The relative 
importance of β-cell upregulation versus insulin-mediated sensitization of target 
tissues to overall maintenance of glucose tolerance remains to be clarified.  The most 
popular index of insulin secretion is perhaps the acute insulin response (AIR) (Cobelli 
et al., 2007). 
 
The mechanisms by which amino acids enhance insulin secretion are varied.  The 
cationically charged amino acid L-arginine does so by direct depolarization of the 
plasma membrane at neutral pH, but only in the presence of glucose.  Other amino 
acids, which are co-transported with Na
+
, can also depolarize the cell membrane as a 
consequence of Na
+
 transport and thus induce insulin secretion by activating voltage 
dependant Ca
2+
 channels.  In general, metabolism of key amino acids appears to be 
necessary for appropriate generation of regulatory signals which then impact upon 
insulin secretion (Newsholme, 2005). 
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The product of insulin response and insulin sensitivity provides a better measurement 
of β-cell function rather than the insulin or C-peptide response examined in isolation.  
When this relationship between insulin sensitivity and insulin secretion is taken into 
consideration, it becomes evident that the subjects who are at high risk of developing 
type II diabetes have demonstrated β-cell dysfunction at a time when they still have 
normal glucose tolerance (Chiasson and Rabasa-Lhoret 2004).  
 
 Insulin resistance seems to be explained mostly by the prevalence of obesity.  The 
concept that β-cell failure is the primary defect leading to the development of diabetes 
is supported by the fact that β-cell dysfunction is present years before the glucose 
intolerance appears.  Chiasson and Rabasa-Lhoret (2004) conclude from their review 
that a decrease in insulin resistance offers a protective effect on the β-cell, and 
therefore has a preservative effect on the β-cell function. 
 
Amino acid metabolism under appropriate conditions, is known to enhance insulin 
secretion from primary islet cells and β-cell lines (Newsholme et al., 2005).  L-
Leucine stimulates insulin release in pancreatic β-cells; L-alanine can stimulate 
insulin secretion under specific conditions of nutrient ability; and L-arginine 
metabolism in the β-cell can give rise to glutamate production and this can influence 
insulin secretion (Newsholme et al., 2005).  It has previously been shown (Broad et 
al., 2008) that L-Carnitine supplemented over a 14 day period, resulted in an 
increased resting plasma glutamate concentration.  Essentially, the potential effects of 
L-Carnitine supplementation on insulin secretion through maintenance of glucose or 
fatty acid oxidation in the β-cell by buffering of acyl-groups, or through generation of 
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glutamate for maintenance of ATP/ADP ratio in the β-cell are attractive as these 
mechanisms of action have previously been demonstrated for other amino acids which 
have been shown to enhance insulin secretion (Kelly, 2000; Newsholme et al., 2005).  
 
The fact that elevations in circulating insulin are generally observed before impaired 
glucose tolerance led to the belief that impaired insulin secretion developed secondary 
to insulin resistance (Biden et al., 2004).  On the other hand, only a minority of obese 
insulin-resistant individuals progress to overt hyperglycemia (Chiasson and Rabasa-
Lhoret 2004), and many do not even display impaired glucose tolerance (Biden et al., 
2004).  This suggests that that insulin resistance is not sufficient in itself to impair β-
cell function but that separate defects, operating at both the level of peripheral tissues 
and the pancreas were necessary for the development of the disease (Butler et al. 
2003).  Type II diabetes can thus now be viewed as failure of the β-cell to compensate 
for insulin resistance by enhancing insulin output (Biden et al., 2004). 
 
2. 6 Carnitine and Exercise 
 
The most important claim in relation to L-Carnitine’s role in improving exercise 
function relates to the role of carnitine in fat metabolism and the marketing claim of 
L-Carnitine promoting fat burning.  L-Carnitine is often advertised to improve fat 
metabolism, reduce fat mass, and increase muscle mass (Maughan et al., 2004) .  This 
is based on the observation that as exercise intensity increases there is a subsequent 
decline in muscle free carnitine availability in support of the hypothesis that a 
decrease in free carnitine availability could possibly by directly responsible for the 
decreased fat oxidation (van Loon et al., 2001).  Endurance athletes may use carnitine 
to increase oxidation of fat during exercise and spare muscle glycogen and athletes in 
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sports such as boxing and horse riding where weight loss and maintenance are 
essential have been reported to use L-Carnitine supplementation (Brass, 2000).   
 
General consumers must beware as it has been shown in a study of 12 over-the-
counter carnitine formulations, the actual mean carnitine content was only 52% of that 
indicated on the label (Millington et al., 1993).  Studies investigating the effect of 
carnitine on metabolism have used in excess of 3g/day, however supplements 
commonly available may contain a maximum of 300mg per serving. 
 
Due to the hypothesis that muscle free carnitine availability can limit fat oxidation 
during conditions of high PDC flux (Stephens et al. 2005; Stephens et al. 2007b; 
Stephens et al. 2007c; Roepstorff et al. 2005; Karlic and Lohninger 2004; van Loon et 
al., 2001), increasing muscle total carnitine content could potentially alleviate the 
decline in fat oxidation rates routinely observed during high intensity exercise (van 
Loon et al., 2001; Brass, 2000; Stephens et al. 2005; Stephens et al. 2006; Stephens et 
al. 2007b).  During intense exercise, carnitine buffers excess acetyl-CoA production, 
forming of acetylcarnitine, when its rate of condensation with oxaloacetate is less than 
its rate of formation by pyruvate oxidation (Constantine-Teodosiu et al. 1991).  
However, this acetylation depletes the free carnitine pool, and it has been suggested 
that the resulting reduction in the availability of free carnitine in the reaction 
catalyzed by CPT I, the rate-limiting step in LCA-CoA entry into the mitochondria 
(McGarry and Brown, 1997), might be limiting to fat oxidation under these conditions 
(Stephens et al. 2005).  If skeletal muscle free carnitine availability were to be 
increased, then the inhibition of fat oxidation observed during exercise could possibly 
be alleviated. 
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2.7 Uptake of Carnitine during Supplementation 
 
A higher muscle carnitine content has been observed in trained humans and equine 
subjects compared to untrained controls (Lennon et al. 1983; Foster and Harris, 1992) 
and the trained subjects have a higher capacity to utilize fatty acids during exercise 
thus promoting a glycogen sparing response (Hawley et al. 1998) .  Since the storage 
in the form of glycogen is limited, the ability to perform high intensity exercise will 
be decreased with progressive glycogen depletion (Brouns, 1997).  An adaptation 
leading to an increased capacity to utilise fatty acids for ATP resynthesis will lead to a 
sparing of endogenous CHO with the consequence that endurance capacity may be 
increased (Bacurau et al. 2003; Karlic and Lohninger 2004).  In order to view this sort 
of response during carnitine supplementation alone, an increase in muscle carnitine 
concentration would have to be observed. 
 
On occasion, muscle carnitine concentration has been shown to increase with long 
term supplementation in patients with chronic renal failure (Ahmad et al. 1990), 
chronic hemodialysis (Siami et al. 1991) and peripheral vascular disease (Brevetti et 
al 1988) but the authors offer no explanation for any effects in these disorders.  One 
potential explanation is that in renal failure patients, dialysis can lead to the filtration 
of carnitine resulting in low carnitine muscle stores (Reda et al., 2003; Poorabbas et 
al., 2007), so a period of supplementation may lead to an uptake of carnitine to that 
higher than the base level.  The duration of carnitine treatment however may be a 
particularly critical variable (Brass, 2000).  It must also be acknowledged that in 
patients with carnitine deficiency, who can have extremely low carnitine tissue levels, 
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diffusion may be an important mechanism by which carnitine is transported to the 
tissues such as skeletal muscle and heart (Wachter et al. 2002) rather than usual active 
transport using OCTN2 transporters. 
 
By supplementing 28mg/kg, intragastrically for the last 4 weeks of a 6 week moderate 
intensity training programme in male Wistar rats, Bacurau et al. (2003) increased fatty 
acid oxidation in skeletal muscle by a mechanism that includes increasing total 
carnitine content within the soleus muscle and increasing the total content of acyl-
carnitine.  This increase in acyl-carnitine concentration was matched by an increase in 
free CoA that enabled Krebs cycle flux enhancement by acting on pyruvate 
dehydrogenase and 2-oxoglutarate dehydrogenase. These results were increased in 
trained rats. 
 
Stephens et al. (2005) was the first study to demonstrate that human skeletal muscle 
total carnitine content can be acutely increased after L-carnitine administration via 
intravenous infusion and that this occurred as a result of an insulin-mediated 
augmentation of muscle carnitine accumulation.  Maintaining plasma carnitine at a 
supraphysiological concentration (500 µmol/L) by infusing L-carnitine for five hours 
however did not measurably increase muscle total carnitine accumulation.  This 
supports the argument that muscle carnitine content cannot be increased by L-
carnitine supplementation alone, and subsequent work on oral L-carnitine 
supplementation has not examined muscle carnitine content but it is estimated it 
would require in excess of 100 days to effect a change in muscle carnitine stores 
(Stephens et al. 2007c) 
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Indeed, further study (Stephens et al. 2007b) has shown that only high circulating 
serum insulin concentrations (≥90 mU/L) are capable of stimulating skeletal muscle 
carnitine accumulation close to the upper physiological limit difficult to achieve by 
dietary means alone.  This finding is in concordance with the hypothesis that insulin 
would augment Na
+
 -dependent skeletal muscle carnitine transport via OCTN2, 
secondary to its action of increasing sarcolemmal Na
+ - 
K
+
 ATPase pump activity and 
therefore intracellular Na
+
 flux (Stephens et al. 2005; Stephens et al. 2006; Stephens 
et al. 2007b; Stephens et al. 2007c) but also show that it will require a relatively high 
serum insulin concentration to achieve this effect (Stephens et al. 2007b). 
 
To try to alleviate this issue, Stephens has aimed to stimulate whether insulin, 
released as a consequence of carbohydrate ingestion could increase the retention of 
carnitine in humans over the course of 1 day or 2 week of L-carnitine supplementation 
(Stephens et al. 2007a).  Plasma total carnitine concentration and urinary total 
carnitine excretion were significantly reduced when L-carnitine ingestion was 
accompanied by carbohydrate feeding.  When analysed along with their previous 
work in the Nottingham lab, they concluded that carbohydrate feeding augments 
whole body carnitine retention in humans.  There is however no muscle data to 
contribute to these findings.  These findings could have a significant effect on the 
integration of fat and carbohydrate oxidation in contracting skeletal muscle as the 
retention is likely to reside in skeletal muscle because insulin is known to stimulate 
muscle total carnitine accumulation (Stephens et al. 2005; Stephens et al. 2006; 
Stephens et al. 2007b; Stephens et al. 2007c).  The elevated muscle glycogen levels 
found also indicate a potential direct insulin action of carnitine (Rodgers et al., 2001). 
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In this final study however (Stephens et al. 2007a) carbohydrate based beverages 
were used and the author acknowledges that any increase in muscle carnitine content 
following a single dose or 2 week of L-carnitine feeding in the presence of elevated 
circulating insulin is likely to be small due to the poor bioavailability of orally 
administered L-carnitine (Harper et al. 1998; Serge et al. 1988; Brass 2000; Stephens 
et al. 2007a).  Thus muscle carnitine accumulation was not measured but estimated 
indirectly using measurements of plasma or urinary carnitine concentrations.  
Carnitine metabolites (TMA etc.) were however not measured which would have 
given a more accurate indication of urinary excretion (Galloway; personal 
correspondence). 
   
The majority of studies have however failed to increase muscle carnitine 
concentration whether it be via oral or intravenous supplementation.  In vivo oral L-
carnitine has been observed to increase plasma L-Carnitine concentrations, but uptake 
in muscle remained unchanged (Fritz, 1967) and this fits well with the observations 
(Engel at al. 1984; Stephens et al. 2007c; Wachter et al. 2002) that L-carnitine is 
taken up by muscle against a concentration gradient – plasma 40 to 60 µmol/L to 
muscle 3 to 4 mmol/L. The gradient is so large that even a substantial oral intake 
would not result in a measurable change.  Intravenous administration of a single dose 
of L-Carnitine for up to 2 weeks failed to show an increase in the working capacity or 
endurance performance in humans (Brass et al. 2004).  Brass et al. (1994) showed 
that muscle carnitine content glycogen utilisation was not modified by carnitine 
administration in any protocols used and hypothesise that any efficacy of carnitine 
modifying exercise performance must therefore reflect either a nonmuscle site of 
action and although muscle carnitine concentration was increased by 17% after 2 x 
32 
 
2g/day supplementation for 3 months in moderately trained subjects (Wachter et al. 
2002), the authors acknowledge that this was not significant and the study had low 
sample numbers and no effect on Pmax, VO2max and RERmax.   
 
There is poor bioavailability of L-Carnitine administered orally (<20% for a 2-6g 
dose; Harper et al. 1998; Serge et al. 1988; Brass 2000; Stephens et al. 2007a) and 
this is potentially the main reason for oral L-Carnitine administration failing to 
increase muscle carnitine concentration and thus alter energy metabolism (Brass, 
2000; Stephens et al. 2007a; Hultman et al. 1991) ).  In humans, the finding that 
intravenous L-Carnitine supplementation also has no impact on muscle carnitine 
content suggests that muscle carnitine transport is most likely the limiting factor to 
muscle carnitine accumulation in humans showing no signs of metabolic disease or 
carnitine deficiency (Stephens et al. 2007c; Wachter et al. 2002).  These observations 
show that beneficial effects of the long-term administration with L-Carnitine on the 
physical performance of healthy subjects cannot be explained by an increase in their 
carnitine skeletal muscle stores.  Altered muscle carnitine handling in 
pathophysiologic states (Brass et al 2004) may be the reason for the increased muscle 
carnitine concentrations in some clinical situations discussed. 
 
2.8 Carnitine in Clinical Conditions 
 
Due to the findings that Carnitine supplementation may not in fact promote fatty acid 
oxidation and may promote carbohydrate metabolism (Galloway and Broad, 2005), 
Carnitine supplementation may be beneficial to those at risk of developing metabolic 
disorders such as impaired glucose tolerance and type 2 diabetes. 
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Indeed,   De Gaetano et al. (1999) observed that intravenous glucose plus carnitine 
administration stimulated glucose disposal calculated through indirect calorimetry 
compared with placebo (glucose plus saline infusion) in healthy subjects.  This 
supported the existence of an insulin-independent action of carnitine, whilst not 
excluding the possibility of an associated insulin-dependant reaction as well.  This is 
consistent with the hypothesis that carnitine induced glucose disposal increased 
glucose oxidation.   They also postulate that carnitine could have a role in the therapy 
of diabetes. 
 
Due to the calorimetric basis of the results obtained (De Gaetano et al., 1999), these 
results should be interpreted with caution.  Indirect calorimetry is the mothod by 
which the type and rate of substrate utilization, and energy metabolism are estimated 
in vivo starting from gas exchange measurements (Ferrannini, 1988).  Indirect 
calorimetry assumes generally that the composition of fats, proteins and 
carbohydrates are sufficiently similar from one food source to another so that the 
corresponding heat equivalent of oxygen and respiratory quotients can be regarded as 
constant (Livesey and Elia, 1988), thus the asumptions and the estimations should be 
interpreted with caution. 
 
Mingrone et al (1999) created at least a short term improvement in insulin sensitivity 
by enhancing whole-body glucose uptake (8%) and increasing glucose storage after a 
two hour infusion of L-carnitine administered to patients with type II diabetes.  These 
results were mirrored in healthy active controls.  The difference in total glucose 
uptake between carnitine and saline infusion was accounted for by a difference in the 
non oxidative disposal of glucose and glucose storage was significantly higher in both 
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controls and diabetic patients under carnitine infusion and the authors raise the 
question as to whether oral carnitine supplementation could possibly produce similar 
effects. 
 
A previous study had shown in a well controlled trial that whole body glucose 
metabolism was significant higher after carnitine infusion in subjects with type II 
diabetes (Capaldo et al. 1991).  They mirrored the results of Ferrannini et al (1988) 
and the results were independent of body weight and the degree of insulin resistance 
experienced by the subjects.  Capaldo (et al. 1991) hypothesise that the majority of 
glucose uptake taken up by the peripheral tissues is directed towards glycogen 
synthesis or complete oxidation. 
 
Again after infusion of ALC over a 3 hour period Giancaterini et al. (2000) increased 
glucose disposal in type II diabetics.  It has been hypothesised that there is a shift in 
substrate utilization from carbohydrates to lipids in type II diabetes, with a large 
proportion of the increase in lipid oxidation accounted for by an increase in 
intramuscular triglyceride mobilization (Kiens et al. 1987).  Giancaterini et al. (2000) 
propose an action for these results: as impaired PDH activity and increased β-
oxidation have been described in type II diabetic patients low dose ALC 
administration could represent a feasible way to physiologically correct this 
enzymatic impairment of substrate utilization. 
 
It has also been shown that administration of L-carnitine holds potential to improve 
insulin sensitivity (Kelly, 2000) in other clinical settings.  Kelly (2000) reviewed that: 
in a study evaluating the effect of parental administration of L-carnitine on metabolic 
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parameters subsequent to post surgical stress, Heller et al (1986) concluded that 
carnitine administration was capable of reducing the associate trend toward insulin 
resistance; and that Gunal (1999) showed a single intravenous dose of L-carnitine had 
a positive effect on insulin sensitivity in patients with renal failure.  Also patients with 
chronic renal failure (Ahmad et al. 1990) and peripheral vascular disease (Brevetti et 
al 1988) have been reported to increase their exercise capacity after treatment with 
carnitine, and carnitine supplementation has also been suggested to be beneficial in 
treating chronic fatigue syndrome (Plyioplys and Plyioplys, 1997). 
 
The work that has been carried out has however been achieved mainly through 
intravenous L-carnitine infusion and little work has researched the use of oral L-
carnitine supplementation, or in those who are not yet at the clinical stage but may 
still be at risk i.e. the obese population.   
 
 
2.9 Non-Clinical Carnitine Supplementation 
 
 
In contrast with the idea of accelerating fatty acid oxidation by carnitine 
supplementation, data from animal heart models suggests that exogenous carnitine 
can induce an increase in glucose oxidation at the expense of fatty acid oxidation 
(Broderick et al. 1992).  The mechanism of carnitine-induced enhanced glucose 
oxidation may involve activation of pyruvate dehydrogenase secondary to reductions 
in acetyl-CoA content as acetylcarnitine is generated (Uziel et al. 1988).   
 
The effect that an increase in skeletal muscle carnitine content had on the integration 
of muscle fat and carbohydrate oxidation during and after hyperinsulinemic clamp 
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conditions was investigated by Stephens and colleagues (Stephens et al. 2006).  Their 
most significant finding was that a 15% increase in skeletal muscle carnitine content, 
achieved via intravenous L-carnitine infusion during a 6-h euglycemic 
hyperinsulinemic clamp conditions resulted in a 30% decrease in muscle PDC activity 
and a 40% decrease in muscle lactate content.  An overnight increase in muscle 
glycogen content was also observed in their carnitine trial again suggesting a direct 
insulin effect of carnitine. 
 
They concluded that the increase in muscle carnitine content observed inhibited 
glycolytic flux (decrease in lactate) and carbohydrate oxidation at the level of the 
PDC, thereby diverting muscle glucose uptake toward glycogen storage (nonoxidative 
glucose disposal).  This would hold potential benefits of carnitine in the use of 
recovery products aimed at glycogen replenishment after exercise.  They propose a 
mechanism whereby the reduction in PDC activation could have been caused by a 
carnitine-mediated increase in skeletal muscle long-chain fatty acid oxidation via CPT 
I.  It could also suggest however, a direct effect of intracellular carnitine on glycogen 
synthase activity and therefore rates of glycogen synthesis. 
 
It has also be shown that steady-state plasma total carnitine concentration was 
significantly lower when L-carnitine was administered intravenously in the presence 
of high (~90 mU/L) and very high (~170 mU/L) serum insulin concentrations 
compared with when serum insulin concentration was maintained at ~10 mU/L 
(fasted) or ~50 mU/L during insulin clamp conditions (Stephens et al. 2007b).  
Collectively, this indicated that insulin will not stimulate muscle carnitine retention 
unless a serum insulin ≥90 mU/L is achieved during hypercarnitinemia.   
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The aim of the present study was to investigate insulin like actions of carnitine on 
healthy active males and sedentary obese subjects.  Due to the findings that Carnitine 
supplementation may not in fact promote fatty acid oxidation and may promote 
carbohydrate metabolism (Hultman et al., 1991; Broderick et al. 1992; Millington et 
al., 1993; Brass et al., 1994; Hawley et al., 1998; Karlic and Lohninger, 2004; 
Maughan et al., 2004, Abramowicz and Galloway, 2005), Carnitine supplementation 
may be beneficial to those at risk of developing metabolic disorders such as impaired 
glucose tolerance and type 2 diabetes.  Obesity is a risk factor associated with IGT, 
dyslipidemia, insulin resistanc, hypertension, hyperurecemia and Impaired Fasting 
Glucose (IFG) (Vega, 2001) and nutritional interventions including L-Carnitine may 
play a role in the reversal of insulin resistance (Kelly, 2000).  This provides the basis 
of the study supplementing to adult males with a BMI which would class them as 
being at risk from developing such metabolic conditions. 
 
Furthermore, if carnitine has an impact upon insulin sensitivity or insulin release in 
response to an oral glucose load it could result in suppressed mobilization of non-
esterified fatty acids (NEFA; Stumvoll et al., 2000) and thus impact upon substrate 
use during low intensity exercise during which plasma derived NEFA’s are a main 
contributor to skeletal muscle oxidation.  This provides the basis for measuring 
substrate use at low intensity exercise in subjects.  
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Chapter 3 - Methods 
 
3.1 Subjects 
Sixteen non-vegetarian males of ranging BMI aged 18-50 years were recruited for this 
study.  Each participant attended the laboratory on 4 occasions over a 5-6 weeks 
period.  Two weeks placebo supplementation followed by two weeks L-carnitine 
supplementation was undertaken together with the completion of food intake diaries 
and exercise logs during this period.  Subject characteristics can be viewed on table 
4.1.1.  The University of Stirling’s Ethics Committee in accordance with the 
Declaration of Helsinki approved the study.   
 
Before taking part in the study, all subjects underwent a routine medical screening 
(height, weight, blood pressure) and completed a general health questionnaire.  
Subjects with any type of metabolic conditions (e.g. type 2 diabetes) were excluded 
from the study.  All subjects gave their consent to take part in the study and were 
aware that they were free to withdraw from the experiment at any point. 
 
3.2 Experimental Protocol 
Each subject was required to visit the lab on 4 different occasions.  During the first 
visit, subjects completed a three stage incremental predicted maximum aerobic 
capacity test.  During this test subjects completed the incremental predicted VO2max 
test on an electronically braked cycle ergometer (Lode Excaliber Sport) in three 
different 3-minute stages, with the workload being increased in relation to heart rate.  
Using the predicted maximum heart rate (220 – age) subject’s maximum aerobic 
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capacity was estimated and from this, the workload required to work at 40% of this 
Predicted VO2max was estimated. 
 
Participants were then assigned to either the lean or overweight / obese groups based 
on BMI and estimated % body fat measurements.  For visits 2, 3 and 4 subjects 
reported to the lab at the same time of day on the same weekday in a fasted state in 
order to participate in an oral glucose tolerance test (OGTT).  These visits were 
separated by two weeks.  The purpose of visit 2 was to perform a preliminary 
familiarisation trial.  This preliminary trial was included to ensure that all participants 
were familiarized with the OGTT protocol and to ensure that the exercise intensity 
was appropriate to achieve a steady state oxygen cost of 40% of predicted VO2max.   
 
On arrival, subjects height, weight and blood pressure was measured.  Subjects were 
then asked to rest in a supine position on a bed while an intravenous cannula was 
inserted into an antecubital vein.  A resting sample (7.5ml) was collected before 
subjects ingested a pre mixed 75g glucose (330ml) drink within 2 minutes (end of 
drink, t= 0 minutes).  Further 7.5ml blood sample was collected at t= 15, 30, 45, 60, 
90 and 120 minutes.  After drawing of samples, a small volume of sterile saline (1-
2ml) was used to flush the cannula to ensure patency. 
 
Five minutes prior to the last sample collection, subjects sat on the electronically 
braked cycle ergometer (Lode Excaliber Sport).  After the final resting blood sample 
was collected, subjects started exercising at 40% of their predicted VO2max for 20 
minutes.  Subjects were asked to cycle at a cadence of between 60-80 RPM that they 
found comfortable, which was kept constant for the 20 minutes and repeated during 
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visits 3 and 4.  Further 7.5ml blood samples were collected at 10 and 20 minutes of 
exercise.    
 
During the exercise time, expired gas was continuously collected and analysed using 
the Sensormedics Vmax29 system in order to measure VO2, RER and the data used to 
estimate rate of carbohydrate and fat oxidation.  Heart rate was also recorded using a 
polar HR monitor at 1 minute intervals to assess cardiorespiratory response to 
exercise.  At the end of the 20 minutes, the workload was decreased and subjects 
pedalled until they reached a heart rate below 120 beats per minute before the 
intravenous cannula was removed. 
 
Previous work in the lab has shown that it can take up to 3 weeks after L-Carnitine 
supplementation for plasma carnitine to undergo a successful wash out period from 
subjects (Broad, unpublished observations).  Hence, we used a single blind ordered 
design with placebo supplementation administered first.  During visits 2 and 3, 
subjects were asked to record food and fluid intake and exercise completed on 3 days 
prior to the trial and then replicate this on each visit.  There was no heavy exercise 
performed on the day before or the morning of the trial.  This allowed them to repeat 
the exact food intake and exercise as they had completed for three days before visit 3 
and 4.  They were also given supplement capsules each containing 0.5g placebo to be 
taken orally two capsules, three times daily for 14 days until the next visit (glucose 
polymer – 3g/day).   
 
Between visits 3 and 4, subjects were again given food intake diaries and exercise 
logs to complete in order to replicate their previous food an exercise intake.  They 
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were also given capsules containing 0.5g L-Carnitine L-Tartrate capsules to be taken 
orally two capsules, three times daily for 14 days until visit 4 (3g/day).  On each visit, 
the final dose was taken the evening before with the subject’s evening meal.  Subjects 
were not aware which supplementation they were taking during the visits and believed 
this to be randomised.   
 
3.3 Blood Collection and Analysis 
Blood samples were drawn into a dry syringe during visits 2, 3 and 4.  They were 
dispersed into one 2.5ml (KEDTA) and one 5ml (Lithium Heparin) blood collection 
tubes.  All samples were immediately mixed and centrifuged at 4000 rpm for 10 
minutes at 4
o
C.  Plasma was transferred to microcentrifuge tubes frozen at –80oC until 
analysis.   
 
Plasma glucose concentration was analysed using mass spectrometry by the glucose 
oxidase (ABX diagnostics) method at a later date.   Plasma insulin (ELISA method, 
DRG human insulin kit) and plasma NEFA (enzymatic analysis, Wako NEFA-C kit) 
were also analysed.  Glucose and insulin data were used to calculate the usual 
sensitivity indices (HOMA-IR, AUC glucose, AUC insulin) with the additional 
parameters of insulin sensitivity index, β cell function (1st phase and 2nd phase), and 
estimated metabolic clearance rate calculated using the methods of Stumvoll et al., 
2000 (Appendix F). 
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3.4 Statistical Analysis 
Changes were compared by repeated measures analysis of variance.  Data from the 
OGTT trials were analysed using a repeated measures analysis of variance 
(RMANOVA) with trial (placebo or carnitine) and time (0 min to 120 min timepoints) 
as within subjects factors and group (lean or overweight / obese) as a between 
subjects factor.  Following observations of a main effect of trial, time, or trial x time 
interaction these were followed up with post-hoc analysis using one-way ANOVA 
and paired samples T-test where appropriate to determine at which location the 
differences occurred.  If a group effect was observed then data was separated into the 
groups and the analysis re-run on each group alone without a between subjects factor.  
Pearson correlation analysis was used to determine whether any relationships existed 
between BMI, estimated % body fat, and predicted VO2max and the magnitude of the 
change in response of the insulin sensitivity indices between placebo and carnitine 
trials.  Data from the exercise task were analysed using RMANOVA with the 120 min 
OGTT values as the exercise period baseline, again using trial and time within 
subjects effects and group as a between subjects effect.  Significance was taken as 
p<0.05. 
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Chapter 4 - Results 
 
4.1 Study Adherence 
 
Subjects were allocated to either the lean (n=8) or overweight/obese (n=8) groups 
after their initial OGTT familiarisation and physical characteristics had been 
determined.  Tables 4.1.1 shows the mean (Standard Deviation) subjects 
characteristics for the whole group and mean (95% CI) for the lean and overweight / 
obese groups.  All subjects completed the study and reported no side effects to the 
supplementation. 
 
Table 4.1.1 Subject Characteristics. Values are mean (SEM) for whole group, and 
mean (95% CI) for lean and overweight / obese groups.   
Variable Whole Group Lean Overweight / 
Obese 
N 16 8 8 
Age (years) 26.5 ± 2.2 24.0 (18.9-29.1) 29.0 (22.2-35.8) 
Height (cm) 179.3 ± 1.5 180.0 (176.0-184.0) 178.7 (174.1-183.3) 
Body mass (kg) 89.7 ± 4.3 76.1 (72.2-80.0)* 103.3 (94.3-112.3)* 
BMI (kg/m
2
) 28.0 ± 1.4 23.5 (22.8-24.2)* 32.5 (29.1-35.9)* 
Estimated body fat (%) 19.1 ± 2.1 12.3 (9.3-14.3)* 25.9 (21.5-30.3)* 
predicted VO2max (L.min
-1
) 4.06 ± 0.19 4.12 (3.67-4.57) 4.01 (3.38-4.64) 
Predicted VO2max (ml.kg
-1
.min
-1
) 46.7 ± 2.8 53.9 (49.3-58.5)* 39.5 (32.2-46.9)* 
Fasting glucose (mmol/L) 5.4 ± 0.2 5.6 (5.1-6.1) 5.1 (4.6-5.6) 
Fasting Insulin 13.7 ± 3.5 6.9 (5.6 – 8.2) 15.4 (5.8 – 23.8) 
* indicates a significant difference between lean and overweight / obese groups 
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4.2 Glucose and Insulin Response to OGTT 
 
Figure 4.2.1 shows the plasma glucose response to the OGTT for all 16 subjects who 
completed the trials.  Repeated measures analysis of variance revealed no significant 
main effect of carnitine supplementation but there was a significant time effect 
(p<0.01) and trial x time interaction (p<0.01) for plasma glucose response to 
supplementation with a lower peak plasma glucose during the OGTT at 30 minutes 
(p<0.05), in the carnitine trial compared with the placebo trial, and a higher plasma 
glucose concentration (p<0.05) at 90 minutes on the carnitine trial compared with the 
placebo trial.  However, ∆ total AUC glucose was not significantly different between 
trials (Figure 4.2.3). 
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Figure 4.2.1 Plasma Glucose Response to OGTT after 14 days of 3g L-Carnitine L-
Tartrate per day.  Data is for n=16.  Values are mean (SEM).  * indicates significant 
difference (p<0.05) from placebo trial.   
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Figure 4.2.2 - Plasma Glucose Response to OGTT for Lean (n=8) and Obese (n=8) 
between L-Carnitnie (LC) and Placebo trials (PL) after 14 days of 3g L-Carnitine L-
Tartrate per day.  Values are mean (SEM).  * indicates significant difference (p<0.05) 
from placebo trial. 
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Figure 4.2.3 Area Plasma Glucose Curve after 14 days of 3g L-Carnitine L-Tartrate 
per day.  Values are mean (SEM).  Data is for n=16 as no main group effect was 
noted.   
 
Plasma insulin peaked at 30 minutes for both the placebo and carnitine trials when 
observing all subjects (figure 4.2.4).  There were however no significant differences 
in plasma insulin levels in response to OGTT after supplementation and no trial, or 
time x trial interaction but there was a significant time effect as expected (p<0.01).  
There was no between-subjects group effect (p=0.16) indicating that the insulin 
response was similar in both the lean and overweight / obese participants (figure 
4.2.3).  Total AUC insulin (figure 4.2.5) was also not different between trials. 
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Figure 4.2.4 Plasma Insulin response to OGTT after 14 days of 3g L-Carnitine L-
Tartrate per day.  Values are mean (SEM).  Data is for n=16.   
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Figure 4.2.5 Plasma Insulin response to OGTT for Lean (n=8) and Obese (n=8) 
subjects after 14 days of 3g L-Carnitine L-Tartrate per day.  Values are mean (SEM).  
Trials are placebo (PL) and L-carnitine (LC). 
 
49 
 
Placebo Carnitine
0
1000
2000
3000
4000
5000
6000
7000
A
U
C
 i
n
s
u
li
n
 
Figure 4.2.6 Area under Plasma Insulin Curve.  Values are mean (SEM).  Data is for 
n=16 as no main group effect was noted.   
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4.3 Other Insulin Sensitivity Responses to OGTT 
 
The estimated first phase and second phase β–cell function was elevated when 
comparing all subjects (P<0.05) as shown in figure 4.3.1.  
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Figure 4.3.1 Estimated first (A) and second (B) phase β–cell function during the 
OGTT on Placebo and L-Carnitine trials after 14 days of 3g L-Carnitine L-Tartrate 
per day. Values are mean (SEM). * indicates significant difference from placebo.  
Data is for n=16 as no main group effect was noted.  Calculated using the methods of 
Stumvoll et al., 2000. 
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There was no change in HOMA-IR (2.6 ± 0.6, PL vs. 2.7 ± 0.4, LC), estimated insulin 
sensitivity index (0.11 ± 0.01, PL vs. 0.11 ± 0.01, LC) or estimated metabolic 
clearance rate (9.4 ± 0.5, PL vs. 9.4 ± 0.5, LC) between trials and no differences in 
response were noted between lean and overweight / obese groups. 
 
 
4.4 NEFA Responses to OGTT with Carnitine Supplementation 
 
There was no significant main effect of trial and no trial x time interaction in the 
plasma NEFA response during the OGTT.  There was a significant time effect 
(p<0.01) with a decline in plasma NEFA occurring throughout the OGTT (figure 
4.4.1). 
 
 
Figure 4.4.1 – Plasma NEFA response to OGTT on the L-Carnitine after 14 days of 
3g L-Carnitine L-Tartrate per day and placebo trials.  Values are mean (SEM).  Data 
is for n=16 as no main group effect was noted.  No significant differences between 
trials.  
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Figure 4.4.2 – Plasma NEFA response to OGTT on the L-Carnitine (LC) after 14 days 
of 3g L-Carnitine L-Tartrate per day and placebo (PL) trials between Lean (n=8) and 
Obese (n=8) subjects.  Values are mean (SEM).  No significant differences between 
trials.  
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4.5 Response to Exercise 
 
End of OGTT (pre-exercise) plasma glucose concentration was not different between 
trials between trials (4.97 (0.25) mM on placebo and 4.68 (0.47) mM on L-Carnitine) 
and there was no significant difference between trials during exercise.  However, a 
trial by group interaction (p<0.05) revealed that plasma glucose was significantly 
lower (p<0.05) in the lean group at 10 minutes of exercise on the carnitine trial 
compared with the placebo trial (4.94 (0.28) mmol/L on placebo vs. 4.14 (0.36) 
mmol/L on carnitine), but this effect was not observed in the overweight / obese 
group (4.64 (0.15) mM on placebo vs. 4.66 (0.31) mM on carnitine).  There was also a 
trial by group interaction for insulin response during exercise (p<0.05) which revealed 
that plasma insulin was significantly higher (p<0.05) in the overweight / obese group 
at the end of exercise on the carnitine trial compared with the placebo trial (9.8 (0.8) 
µlU/mL on placebo vs. 13.7 (1.8) µlU/mL on carnitine), but this effect was not 
observed in the lean group (7.2 (0.7) µlU/mL on placebo vs. 7.2 (0.9) µlU/mL on 
carnitine). 
 
Statistical analysis revealed that there was no significant change in Heart Rate or VO2 
respectively, during 20 minutes exercise at 40% of predicted VO2max following a 2 
hour OGTT between trials.  Mean (SEM) heart rate was 114 (3) b.p.m. on the placebo 
trial and 111 (4) on the carnitine trial, mean (SEM) VO2 was 1.69 (0.11) L.min
-1
 on 
the placebo trial and 1.70 (0.11) L.min
-1
 on the carnitine trial but neither of these were 
significant differences.  Mean (SEM) RER during the steady state (40% of predicted 
VO2max) exercise period was 0.77 (0.02) on the placebo trial and 0.77 (0.02) on the 
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carnitine trial and as a result total carbohydrate oxidation and total fat oxidation rates 
were not different. 
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Figure 4.5.1 Heart Rate at 40% of predicted VO2max following a 2 hour OGTT after 
14 days of 3g L-Carnitine L-Tartrate per day.  Values are mean (SEM).  Data are for 
n=16 as no main group effect was noted. 
 
 
55 
 
0 5 10 15 20
0.50
1.00
1.50
2.00
2.50
PL
LC
Exercise time (min)
V
O
2
 (
L
. m
in
-1
)
 
Figure 4.5.2 VO2 at 40% of predicted VO2max following a 2 hour OGTT after 14 
days of 3g L-Carnitine L-Tartrate per day.  Values are mean (SEM).  Data are for 
n=16 as no main group effect was noted. 
 
There was no difference at the end of OGTT (pre-exercise) plasma NEFA 
concentration between trials and no difference in the end of exercise concentrations 
(exercise t=20) as shown in figure 4.5.3. 
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Figure 4.5.3 – Plasma  NEFA response to submaximal exercise on the placebo and 
carnitine trials after 14 days of 3g L-Carnitine L-Tartrate per day.  Date is for n=16 as 
no main group effect was noted.  Values are mean (SEM).  No difference between 
trials. 
 
4.6 Correlations Between Change in Variables in Response to Carnitine 
Supplementation with BMI, Body Fat and Predicted VO2max 
 
There were significant correlations between the change in AUC glucose with BMI, 
estimated % body fat and predicted VO2max (Table 4.6.1).  A positive correlation was 
noted for change in AUC glucose with BMI and % body fat with a lower BMI and a 
lower % body fat being associated with a lower (more negative) change in AUC 
glucose.  A negative change in AUC glucose means a lower total AUC glucose on the 
carnitine trial compared with placebo.  However, a negative correlation was observed 
for change in AUC glucose to predicted VO2max with those having a higher predicted 
VO2max also having a lower (more negative) change in AUC glucose.  In addition, 
change in AUC glucose was significant positively correlated with change in AUC 
insulin as expected (Pearson correlation 0.55, p<0.05) showing that a lower AUC 
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glucose response was associated with a lower total AUC insulin in the OGTT on 
carnitine.   
 
Table 4.6.1 – Correlates of change (∆) in insulin sensitivity indices and calculated 
parameters following carnitine supplementation to BMI, % body fat and predicted 
VO2max.  Values are Pearson correlation coefficients (p-value).  N = 16 
 
Variable BMI % Body Fat predicted 
VO2max 
∆AUC glucose 0.58 (0.02)* 0.65 (0.01)* -0.65 (0.01)* 
∆AUC insulin 0.34 (0.22) 0.42 (0.12) -0.30 (0.28) 
∆1st phase β-cell function 0.00 (0.99) -0.10 (0.72) -0.05 (0.86) 
∆2nd phase β-cell function 0.00 (0.99) -0.10 (0.72) -0.07 (0.81) 
∆Insulin Sensitivity Index -0.37 (0.20) -0.46 (0.10) 0.46 (0.10) 
∆Metabolic Clearance Rate -0.39 (0.17) -0.48 (0.09)┼ 0.46 (0.10) 
∆HOMA-IR 0.07 (0.83) 0.14 (0.65) -0.05 (0.88) 
*significant correlation between variables. ┼ tendency to be significant (p<0.10) 
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Chapter 5 – Discussion 
 
5.1 Main Findings 
The main finding of the present study was that two weeks supplementation of L-
Carnitine L-Tartrate (3g/day) significantly reduced peak glucose when assessed using 
an oral glucose tolerance test.  This was more apparent in lean, active individuals than 
obese / sedentary subjects.  Other findings included that β cell function (1st phase and 
2
nd
 phase) was increased after LC supplementation, however this was calculated using 
the methods of Stumvoll et al., 2000 of which the peak glucose concentration plays a 
direct part. 
 
5.2 Carnitine and glucose disposal / oxidation 
One proposed mode of action for the reduced peak glucose shown after LC 
supplementation could be an increased uptake and storage of glucose in skeletal 
muscle.  Stephens et al. (2006), increased skeletal muscle carnitine content and 
observed a decrease in muscle lactate content and PDC activity and increased 
glycogen storage in conditions of high carbohydrate availability. The authors 
attributed the response to a possible carnitine-mediated increase in muscle fat 
oxidation, as muscle LCA-CoA was increased.  Although muscle carnitine was not 
measured in the present study, it would have been unlikely in the current study that 
muscle carnitine was altered as oral supplementation in excess of 100 days may be 
required to alter muscle carnitine concentrations (Stephens et al., 2007c).  Therefore 
an alternative mechanism for increased glucose disposal could be proposed that would 
fit the current observations and those of Stephens et al. (2007c) of carnitine mediated 
glucose uptake. 
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The blunting of peak glucose concentration to a glucose challenge following LC 
supplementation despite similar insulin release in the current study indicates that 
plasma carnitine levels may have direct insulin like effect.  This direct insulin like 
effect may be on tissues such as skeletal and cardiac muscle, or could play a 
metabolic role in buffering acyl groups in β-cell mitochondrial metabolism which 
would act to maintain glucose oxidation and thus potentially enhance insulin release 
for a given glucose concentration (Gonzalez-Ortiz et al., 2008).  Newsholme et al., 
(2005) suggests that amino acids which are co-transported with Na
+
, can also 
depolarize the cell membrane as a consequence of Na
+
 transport and thus induce 
insulin secretion by activating voltage-dependant Ca
2+
 channels.  The work of 
Stephens and colleagues ((Stephens et al., 2005; Stephens et al., 2006; Stephens et al., 
2007b; Stephens et al., 2007c) has shown the skeletal muscle carnitine accumulation 
can be manipulated close to the upper physiological limit difficult (Stephens et al., 
2007b) to achieve by creating a serum insulin concentration greater than 90 mU/L. 
This is in concordance with the hypothesis that insulin would augment Na
+
-dependant 
skeletal muscle carnitine transport via OCTN2 (Newsholme et al 2005), secondary to 
it’s action of increasing sarcolemmal Na+- K+ ATPase pump activity and therefore 
intracellular Na
+
 flux.  There theory is enhanced given the change in glucose disposal 
in combination with no significant differences in insulin levels (Figures 4.2.2 and 
4.2.5). 
   
The potential for LC to reduce peak plasma glucose through a direct insulin like 
action is supported by previous observations of insulin like actions of physiological 
concentrations of carnitine on rat cardiac muscle (Rodgers et al., 2001) and the 
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observed increased skeletal muscle glycogen storage following carnitine infusion in 
humans (Stephens et al., 2006).  The insulin like action of L-Carnitine could explain 
lower peak glucose observed during the OGTT in the present study if there was no 
increased non-oxidative glucose disposal but the absence of skeletal muscle biopsy 
data does not allow us to confirm whether our likely modest increase in fasting 
plasma carnitine concentration of between 50-100% of normal fasting concentration 
(Galloway and Broad, 2005) is sufficient to induce this action. 
 
Stephens et al., (2006) estimated that the difference in skeletal muscle glycogen 
content (glucosyl units) between control and carnitine at 24h was approximately 170 
Mmol/kg dry muscle or 40mmol/kg wet muscle.  Because of carnitine’s role in long 
chain fatty acid translocation (Reda et al., 2003; Karlic and Lohninger 2004), it is 
entirely plausible that a reduction in PDC activation could have been caused by a 
carnitine mediated increase in skeletal muscle activation via CPT I (Stephens et al. 
2006).  The decrease of PDC activity after the insulin clamp in their trial was 
paralleled by a reduction in muscle lactate content and resulted in an accumulation of 
muscle glycogen overnight, conditions that are consistent with the idea that 
carbohydrate oxidation was inhibited.  In support of this theory, muscle Long chain 
acetyl-CoA content returned to basal overnight during the carnitine visit (whereas is 
remained suppressed during the control visit), which would also suggest an increase 
in fat oxidation. 
 
In contrast to this suggestion, the results of the Stephens et al. (2006) study could also 
suggest a direct effect of intracellular carnitine on glycogen synthase activity and 
therefore rates of glycogen synthesis.  An increase in glycogen synthesis would 
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reduce the amount of glucose entering glycolysis under insulin clamp conditions and 
therefore pyruvate and lactate accumulation and PDC activity.  The decrease in 
muscle lactate content and PDC activity was evident however, before the increase in 
muscle glycogen content.  Thus this mechanism is unlikely. 
 
Similarly to the present study, De Gaetano et al. (1999) observed that carnitine 
increased the rate of glucose disposal compared with placebo.  De Gaetano et al. 
(1999)  used intravenous carnitine infusion to increase circulating carnitine levels and 
whole body-glucose uptake was measured using the Frequently Sampled I.V. Glucose 
Tolerance Test.  Their results support the existence of an insulin-independent action 
of carnitine while not excluding the possibility of an associated insulin-independent 
action as well.  Glucose oxidation rate, calculated through indirect calorimetry, was 
significantly increased after carnitine intravenous bolus.  The authors acknowledge 
that results obtained from the calorimetric analysis have to be interpreted with 
caution.  They also proposed no modes of actions for the results that they observed. 
 
De Gaetano et al. (1999) postulate that carnitine might play a role in the therapy of 
diabetes mellitus by improving insulin sensitivity and work has been completed using 
clinical populations (Mingrone et al. 1999; Ferrannini et al. 1988; Capaldo et al. 
1991; Giancaterini et al. 2000; Kelly, 2000; Heller et al 1986; Gunal 1999; Ahmad et 
al. 1990; Brevetti et al 1988; Plyioplys and Plyioplys, 1997).  Whilst studying 
patients with type II diabetes Giancaterini et al. (2000) intravenously increased acetyl 
L Carnitine plasma concentrations and observed a higher glucose uptake.  No 
significant effect was demonstrated on glucose oxidation or lipid oxidation even with 
high doses of Carnitine infusion.   
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In addition, Rahbar et al., (2005) have observed lowering of fasting glucose following 
12 weeks of carnitine supplementation in patients with type II diabetes, and Power et 
al., (2007) have subsequently also confirmed these observations in a mouse model 
and suggest that carnitine could be used as an adjunctive therapy in diabetes.  
Furthermore, Poorabbas et al., (2007) have observed that plasma carnitine 
concentration is significantly lower in patients with complications associated with 
their type II diabetes (retinopathy, neuropathy and hyperlipidaemia).  However, some 
confusion exists in the literature due to other poorly powered studies (n=6) that have 
not observed these beneficial actions of carnitine in type II diabetes patients.  Taken 
together, the results of the previous studies discussed here points towards an 
extracellular effect of carnitine most likely influencing glucose uptake by tissues such 
as cardiac and skeletal muscle or liver. 
 
One point the authors consider is the availability of ALC at the intracellular effector 
level.  Two pools of acetyl-coA molecules coexist in the cell: the larger one is located 
in the mitochondria and the smaller one in the cytosol.  The mitochondrial acetyl-CoA 
pool derives directly from the β-oxidation of long chain acyl-CoA and indirectly from 
pyruvate decarboxylation catalyzed by the PDC, ALC infusion very likely produces 
an increase in the acetyl-CoA cytosolic pool and simultaneously increases the ALC 
cellular concentration, forcing the passage of the acetyl moieties across the 
mitochondrial membrane.  Therefore, an inhibition of intramitochondrial acyl-CoA β-
oxidation would occur with a subsequent reduction of acetyl-CoA formation.  As 
observed in animals, the natural consequence of this process should be an inhibition 
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of FFA oxidation and a simultaneous increase of glucose storage (Mingrone et al., 
1999). 
 
Mingrone et al. (1999) observed that glucose oxidation, evaluated by indirect 
calorimetry measurements, significantly increased in type II diabetic patients after 
carnitine infusion, while in normal controls glucose oxidation under carnitine was not 
significantly modified from the saline infusion value.  Carnitine was administered by 
intravenous infusion.  L-carnitine infusion also stimulated glucose uptake in both 
healthy and type II diabetic patients.  In type II diabetic patients, in whom a defect of 
the PDH activity is present, L-carnitine would normalize PDH activity, thus 
stimulating oxidative utilization of glucose.  In other words, when PDH is normally 
active, as in the case of the healthy subjects, the excess glucose uptake induced by the 
carnitine could be accumulated in the cells as glycogen.  When it overcomes the 
capacity of the cell (already highly stimulated by insulin) to oxidize glucose: on the 
contrary, when PDH activity is impaired, such as in diabetic patients (Mingrone et al. 
1999), L-carnitine would enhance it. 
 
Mingrone et al. (1999) support this hypothesis by analysing evidence that derives 
from the observed fall in plasma concentration of lactate in L-carnitine-infused 
diabetic patients.  An important enzyme in catalyzing the rate-limiting step in lactate 
utilization is PDH, and a decrease in PDH activity would result in a reduction of the 
oxidation of pyruvate to acetyl-CoA and could contribute to an increased conversion 
of pyruvate to lactate via lactate dehydrogenase (Mingrone et al., 1999).  Since there 
is evidence that L-carnitine stimulates the activity of PDH (Broderick et al., 1991), 
the observation of an increase in oxidative glucose utilization during L-Carnitine 
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infusion in diabetic patients (Mingrone et al., 1999) could be explained by carntines 
ability to overcome the defect of PDH activity in type II diabetic patients. 
 
The mechanism proposed underlying the improvement in glucose disposal induced by 
intravenous carnitine infusion in type II diabetic patients by Capaldo et al. (1991) 
again focuses around the majority of glucose taken up by peripheral tissues being 
directed towards glycogen synthesis or complete oxidation.  They also showed a 
pronounced decline in lactate concentration during carnitine infusion mirroring that 
shown by Mingrone et al. (1999). 
 
5.3 Combined Carnitine and Carbohydrate Supplementation 
 
It has been shown (Stephens et al. 2007a) that plasma total carnitine concentration 
and urinary total carnitine excretion were significantly reduced when L-carnitine 
ingestion was accompanied by carbohydrate feeding.  The conclusion from this 
particular work was that carbohydrate feeding augments whole body carnitine 
retention in humans.  Given that skeletal muscle is the major site of carnitine storage 
within the body (Brass, 1995), and that maintaining hypercarnitinemia for 5 hours in 
the presence of hyperinsulinemia increases skeletal muscle total carnitine 
accumulation (Stephens et al. 2005; Stephens et al. 2007c) as was achieved in this 
study (Stephens et al. 2007a), it is not unreasonable to suggest that the greater 
retention occurred mainly in the muscle.  This finding is in concordance with the 
hypothesis that insulin, released as a consequence of carbohydrate ingestion,  would 
augment Na
+
 -dependent skeletal muscle carnitine uptake by increasing Na
+ - 
K
+
 
ATPase pump activity in humans (Stephens et al. 2005; Stephens et al. 2006; 
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Stephens et al. 2007b; Stephens et al. 2007c).  Essentially, elevated plasma carnitine 
concentration together with carbohydrate ingestion would promote an increase in 
glucose uptake. 
 
Although subjects in the present study were advised to take 2 x 0.5g L-Carnitine L-
Tartrate three times a day (3g/day) with a meal, this was not tightly controlled.  Also, 
total carnitine concentration and urinary total carnitine excretion were not measured.  
Thus, to credit the decrease in peak glucose concentration to an increase in muscle 
glycogen synthesis (Stephens et al., 2006) stimulated by increased muscle carnitine 
concentration would be conjecture.   
 
5.4 Exercise Response 
 
All subjects completed 20 minute exercise at 40% of predicted VO2max after the 2 
hour OGTT.  There was no difference in the end of OGTT (pre-exercise)  plasma 
glucose concentration and plasma NEFA concentration between trials and no 
difference at the end of exercise.  There was also no significant difference between 
heart rate, RER and VO2 during 20 minutes of steady state exercise at 40% predicted 
VO2max.  Thus, although increased glucose disposal was observed at rest, LC had no 
effects on exercise metabolism. 
 
Although nor significant, heart rate did appear to be lower at each time point during 
the exercise on the L-Carnitine trial (figure 4.5.1).  A trial by group interaction 
revealed that blood glucose was significantly lower in the lean group after 10 minutes 
of exercise after carnitine supplementation compared with the placebo trial and a trial 
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by group interaction also revealed that plasma insulin was significantly higher in the 
overweight / obese group after carnitine supplementation compared with placebo. 
 
Rodgers et al., (2001) showed for the first time that a physiologically relevant 
concentration of carnitine exerts insulin-like metabolic effects on the intact heart.  The 
actions of 50µM carnitine and 75 mU/L insulin were very similar on all 
measurements and specifically carnitine mimicked insulin’s actions on glycolysis, 
glucose oxidation, pyruvate oxidation and palmitate oxidation with both timing and 
duration of responses similar.  The heart rate results observed in the present study 
may be attributed to the increase rate of glycolysis as observed by Rodgers et al., 
(2001). 
 
No change in RER, VO2 muscle lactate, plasma lactate and muscle glycogen was 
observed at low intensity and high intensity exercise in a previous study (Brass et al., 
1994) which used varying doses of 2 hours intravenous carnitine infusion but without 
glucose ingestion.  The authors argue that carnitine does not modify any important 
parameters of fuel metabolism during exercise in healthy subjects, attributed to the 
fact that short term administration of carnitine would have little impact on muscle 
carnitine metabolism (Fritz, 1967; Brass et al., 1994; Stephens et al,. 2005; Stephens 
et al. 2007a; Stephens et al. 2007b; Stephens et al. 2007c; Engel et al. 1984; Wachter 
et al. 2002; Hultman et al. 1991; Brass et al., 2000).  Brass et al., (2004) conclude that 
short term administration of carnitine has no effect on exercise physiology in normal 
subjects and that the efficacy of carnitine in modifying exercise performance must 
therefore reflect either a nonmuscle site of action, altered muscle carnitine handling in 
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pathophysiologic states or altered muscle carnitine content caused by long term 
carnitine administration (as supported by Stephens et al. 2007c). 
 
It has previously been shown that a combination of hypercarnitinemia (~500 µmol/l) 
and hyperinsulinemia increased muscle total carnitine content (Stephens et al., 2005).  
This particular Stephens study (Stephens et al., 2005) demonstrated that insulin could 
acutely increase muscle total carnitine content in humans during hypercarnitinemia, 
which is associated with an increase in OCTN2 transcription. 
 
Stephens et al., (2006) later established that a threshold exists for the stimulatory 
effect of insulin on plasma L-Carnitine clearance in humans.  They concluded that 
insulin can stimulate plasma carnitine clearance, most likely into skeletal muscle, but 
only when insulin is present at a physiologically high concentration (≥90 mU/l).  It 
must be noted however, that muscle carnitine was not directly measured by Stephens 
et al. (2006).   
 
In the present study, subjects were advised to supplement 3g/day L-Carnitine L-
Tartrate (3 x 1g with meals).  Although these meals were not controlled (except for 
asking of a repetition between trials) subjects would be experiencing increased insulin 
concentrations at the point of carnitine administration.  During the OGTT trials, 
plasma insulin reached 76.5 mU/l and 79.6 mU/l for the placebo and carnitine trials 
respectively after oral administration of 75g glucose.  Although, not at the level 
Stephens et al., (2006 insulin) found to stimulate plasma carnitine clearance  (≥90 
mU/l), perhaps the repeated administration of carnitine with meals and the resulting 
increase in insulin may promote a similar effect.  It must however be acknowledged 
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that for oral administration of L-Carnitine in the present study, it has been concluded 
that over 100 days of supplementation may be required to increase muscle carnitine 
concentration (Stephens et al., 2007c).  For this reason, we can conclude that any 
effects we have observed will be due to an action of carnitine outside the muscle. 
 
Work examining 2 weeks L-Carnitine supplementation saw enhanced carbohydrate 
metabolism in males working at 64% VO2max for 30 minutes (Abramowicz and 
Galloway, 2005).  The relevance to the current study is that carnitine was 
administered orally (3g/day) with a carbohydrate based meal.  It does thus seem as if 
supplemental carnitine ingested with carbohydrate over a period of two weeks can 
increase carbohydrate oxidation at rest (Ferrannini et al., 1988) and exercise 
(Abramowicz and Galloway, 2005).  This has also been demonstrated in working 
heart models where increases in glucose oxidation have been observed when carnitine 
is added to the perfusate (Broderick  et al., 1992; Lopaschuk, 2000).  Thus an increase 
in carbohydrate oxidation could be observed if greater glucose disposal was leading to 
greater glycogen storage (Stephens et al., 2007a). 
 
Wachter et al., (2002) increased skeletal muscle carnitine content by 17% in healthy 
moderately trained males after 3 months supplementation, but this was not a 
significant result.  Again, like the previous study there was no effect during exercise 
at 40% VO2max on VO2, RER or Heart Rate.  There was also no change at exercise 
intensities of 20% and 60% VO2max and no effect on blood lactate. 
 
Short term carnitine administration (2 hours intravenous administration of 185 
µmol/kg carnitine) has shown no effect on exercise physiology in normal subjects 
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(Brass et al., 1994).  Perhaps for short term administration as was administered in the 
Stephens et al., (2007b) and the Brass et al., (1994) studies, the plasma insulin levels 
may be required to be manipulated to a physiologically high concentration (≥90 
mU/l).  It has also been demonstrated that as exercise intensity increase to > 70% 
VO2max, muscle free carnitine falls to ~ 30% (5.6 mmol/kg dm) of the total carnitine 
store and is paralleled by a 35% decrease in the rate of fat oxidation (van Loon et al. 
2001).  Exercise intensity and training status may also play an important element in 
the response to carnitine supplementation as these are key determinants of substrate 
selection (Wachter et al., 2002; Karlic and Lohninger, 2004; Bacarau et al., 2003).   
 
Carnitine administration did not increase muscle carnitine content or physical 
performance when administered long term (2 x 2g/day for three months) in 
moderately trained humans (Wachter et al., 2002) however high intensity exercise 
resulted in a significant increase in plasma short-chain acylcarnitine concentration 
compared with low intensity exercise.   Trained rats also showed an increase in 
mitochondrial carnitine after supplementation when compared with sedentary rats 
(Bacarau et al., 2003). 
 
In summary, the observations in the present study that may be as a result of the 
hypothesis that carnitine is not modifying any important parameters of fuel 
metabolism during exercise in healthy subjects, attributed to the fact that short term 
administration of carnitine would have little impact on muscle carnitine metabolism 
(Fritz, 1967; Brass et al., 1994; Stephens et al,. 2005; Stephens et al. 2007a; Stephens 
et al. 2007b; Stephens et al. 2007c; Engel et al. 1984; Wachter et al. 2002; Brass et al. 
2004; Hultman et al. 1991; Brass et al., 2000).  The present study was a two week 
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dose of oral L-Carnitine L-Tartrate, but as we have previously discussed, this protocol 
would have been unlikely to impact upon muscle carnitine metabolism. 
 
At the onset of exercise, signals from inside and outside the muscle cell increase the 
availability of carbohydrate and fat to provide the fuel required for ATP production.  
There is room for shifts between the proportion of energy that is provided from CHO 
and fat.  It has long been known that increasing the availability of endogenous or 
exogenous CHO can increase the oxidation of CHO and decrease the oxidation of fat 
(Spriet and Watt, 2003). 
 
In the current study, the lean population were also active and this may explain the 
greatest glucose lowering effect of supplementation.  Glucose ingestion before 
exercise results in increased plasma glucose and insulin, PDH activity and reduced 
plasma Free fatty acids (Spriet and Watt, 2003).  Coyle et al. (1997) demonstrated 
reduced entry of long chain fatty acids into the muscle and the mitochondria 
following CHO ingestion in endurance trained men. 
 
 
5.5 Possible Mechanisms of Action 
 
It would not be unreasonable to propose that an increase in the muscle carnitine pool 
following prolonged oral supplementation may in part be related to both exercise 
training status and combined carnitine and carbohydrate meal ingestion (Abramowicz 
and Galloway, 2005).  Carnitine supplementation increased the total amount of 
carnitine in the mitochondria by 49.4% in sedentary rats and by 79.5% in trained ones 
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indicating that the association between supplementation and moderately-intensity 
training seems to be much more efficient in promoting carnitine incorportation into 
soleus muscle cells (Bacarau et al., 2003). 
 
5.6 Fat Oxidation Response 
 
In the present study, there was no significant main effect of trial and no trial x time 
interaction in the plasma NEFA response during the OGTT.  There was also no 
difference at the end of OGTT (pre-exercise) plasma NEFA concentration between 
trials and no difference in the end of exercise concentrations as shown in figure 4.5.3.   
Exercise RER was not different further indicating no effect on fat metabolism at an 
exercise intensity 40% VO2max after L-Carnitine supplementation.   This supports the 
majority of the literature in that oral carnitine supplementation does not influence 
fatty acid mobilisation (Hultman et al., 1991; Broderick et al. 1992; Millington et al., 
1993; Brass et al., 1994; Hawley et al., 1998; Karlic and Lohninger, 2004; Maughan 
et al., 2004, Abramowicz and Galloway, 2005). 
 
Muller et al., (2002) however did observe that L-Carnitine significantly increased 
fatty acid oxidation.  Muller et al., (2002) assessed fatty acid oxidation by the 
cumulative 
13
CO2 exhalation method.  Following the same protocol as Muller et al., 
(2002), Wutzke and Lorenz (2004) also observed increased fatty acid oxidation by the 
cumulative 
13
CO2 exhalation method in obese subjects.  Both studies however 
measured their subjects at rest whereas fat oxidation rates in the present study were 
measured during exercise using indirect calorimetry.   Supplementation was similar 
(3g/day) in all studies (for 14 days in the present study and 10 days in the Muller et 
al., (2002), Wutzke and Lorenz (2004) studies) but the present study used male 
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subjects only.  Both methods of measurement are equally reliable, thus more work is 
required in the future using the protocol of the present study but measuring whole 
body indirect calorimetry at rest as well as exercise.  Wutzke and Lorenz (2004) 
acknowledge that the measured 
13
CO2 exhalation over 14 hours reflects mainly the 
dietary fat oxidation and that their observation of an increased fat oxidation during LC 
supplementation does not correspond to the findings of unchanged body fat mass, 
total body water, lean body mass and body weight within their supplementation 
period.  Muller et al. (2002) attribute their finding to increased serum carnitine 
concentrations after supplementation but proposed no mechanisms for their observed 
increase in fatty acid oxidation. 
 
5.7 Potential Role of Incretins in Response to Carnitine 
The gastrointestinal tract is increasingly viewed as a critical organ in glucose 
metabolism because of its role in delivering glucose to the circulation and in secreting 
multiple glucoregulatory hormones that, in concert with insulin and glucagon, 
regulate glucose homeostasis (Maggs et al., 2007).  A change in gastrointestinal tract 
function, or a change in gastric emptying may also explain the plasma glucose 
concentration results observed.  Indeed, a slowing in the rate of gastric emptying 
would also appear to explain what seems to be a delayed insulin response and / or 
slower appearance of glucose into the circulation.  Gastric emptying is a complex 
process, dependent on many factors including the physiochemical composition of 
food, the integration of motor activity in the stomach and duodenum, the nutrient- and 
mechanoreceptor-mediated feedback from receptors in the lumen of the small 
intestine and the secretion of gastrointestinal hormones (Hunt et al. 1968; Horowitz et 
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al., 1994).  Prior nutrient intake may influence subsequent gastric emptying function 
(Maggs et al., 2007). 
 
Glucose-dependent inhibitory peptide (GIP) and glucagon- like peptide-1 (GLP-1) are 
incretin hormones that are released in response to carbohydrate- and lipid containing 
meals (Herrmann-Rinke, et al., 1995; D’Alessio, et a., 2004).  GIP has lost most of its 
insulinotropic activity in patients with type 2 diabetes: GLP-1 in contrast, shows 
promise as a potential diabetes treatment primarily because of its ability to enhance 
glucose-stimulated insulin secretion, slow gastric emptying and inhibit glucagon 
secretion, all of which act to regulate plasma glucose concentrations in patients with 
type 2 diabetes (Maggs et al., 2007).  However, little is known about incretin 
responses in healthy and overweight / obese populations of the potential role of 
carnitine on secretion of incretin hormones.  In relation to the current study, the 
incretin principles are of interest but the question of what potential effects may be 
occurring in healthy active, and overweight sedentary populations must be raised. 
 
As previously discussed, the blunting of peak glucose response to a glucose challenge 
following LC supplementation despite similar insulin release in the current study 
indicates that plasma carnitine levels may have a direct insulin like effect.  The 
potential for LC to reduce peak plasma glucose through a direct insulin like action is 
supported by previous observations of insulin like actions on rat cardiac muscle 
(Rodgers et al., 2001) and the observed increased skeletal muscle glycogen storage 
following carnitine infusion in humans (Stephens et al., 2006).  With GLP-1’s ability 
to enhance glucose-stimulated insulin secretion, slow gastric emptying and inhibit 
glucagon secretion, there is potential that carnitine may influence GLP-1.  Potentially, 
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an increased incretin response (GLP-1) could promote an increase insulin response for 
a given glucose concentration and explain the observations in the present study of a 
lower peak glucose concentration after carnitine supplementation whilst insulin levels 
remained unchanged. 
 
5.8 Limitations of Study 
 
It must be acknowledged that the plasma glucose and insulin samples were frozen 
immediately after separation.  Giampeitro et al., (1980) showed a significant positive 
relation, although minimal, between storage interval and percentage decrease in 
glucose concentration when frozen at -20
o
C.  In the present study, prompt separation 
after blood withdrawal would have avoided glucose degradation, and storage at -80
o
C 
would also have alleviated this issue. 
 
It must also be acknowledged that no muscle tissue was collected and plasma 
carnitine concentrations were not measured. 
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Chapter 6 - Conclusion 
 
6.1 Conclusion 
Although the present data does not allow concrete conclusions to be drawn as to the 
mechanisms responsible for the results, we have shown that 2 weeks L-Carnitine L-
Tartrate supplementation can decrease peak glucose levels during an OGTT despite 
similar insulin responses between control and L-Carntine trials.  This may be 
attributed to either a decreased rate of gastric emptying, an increased incretin 
response, with GLP-1 being of particular interest, or increased oxidative or non-
oxidative glucose disposal into skeletal muscle.  These results may also be attributed 
to a direct insulin like carnitine response, although with the supplementation 
timescales, it is unlikely that muscle carnitine concentration would increase, but the 
dose administered should be sufficient to raise resting plasma carnitine levels by 
around 50% - 100%. 
 
6.2 Recommendations for Future Study 
It is recommended that oral L-Carnitine supplementation warrants further 
investigation following the protocol used in the present study.  Of particular interest, 
would be plasma carnitine levels, muscle carnitine concentrations and muscle 
glycogen levels.   By also measuring incretin response and carnitine effects on β-cell 
function in vitro, this would help to either confirm or deny that incretins, especially 
GLP-1, or β-cells were contributing to an insulin like effect due to carnitine 
supplementation.  Rate of gastric emptying data would also provide interesting 
reading. 
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Should carnitine be shown to have a direct insulin like effect, then further research 
should be conducted looking at the practical implications of such findings for clinical 
situations such as subjects with impaired glucose tolerance, and type II diabetes. 
 
It is also recommended that further study is warranted focussing on an elite athlete 
population.  The hypothesis that carnitine supplementation may increase muscle 
glycogen holds potential to improve endurance performance or recovery from 
exercise especially at the elite level where small differences could be the difference 
between winning and losing. 
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APPENDIX A 
 
The effects of L-carnitine supplementation on response to glucose 
ingestion and on fat metabolism at rest and during exercise. 
 
Principle Investigator: Thomas Craig 
Other Investigators: Dr Stuart Galloway 
 
You are being invited to take part in a research study.  Before you decide to 
participate, it is important for you to understand why the research is being 
done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
What is the purpose of the study? 
There has been an increasing interest in the role that L-carnitine 
supplementation may play in the fuels utilised by the body.  Some reports 
suggest that it may enhance fat metabolism whereas others suggest that it 
may be the opposite and enhance glucose (carbohydrate metabolism)  The 
purpose of this study is thus to test the theory that the use of L-carnitine 
supplementation may improve insulin sensitivity, enhance whole body glucose 
uptake, increase glucose storage and possibly improve fat metabolism at rest 
or during exercise.   
 
Why have I been chosen? 
You have been chosen as you may have a BMI (Body Mass Index) that 
suggests you are overweight and sedentary or that you are lean and active. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
 
What do I have to do? 
This study will require you to attend the Gannochy Sports Centre at the 
University of Stirling on 4 separate occasions over a five week period.  The 
first visit will involve a predicted maximal aerobic test using a cycle ergometer 
(gym cycle) to measure your predicted maximum exercise capacity.  This will 
necessitate you to cycle at increasing workloads while we monitor your heart 
rate and breathing.  We have chosen to use a predicted maximal aerobic test 
in order to decrease any stress or discomfort you may feel.  The visit will last 
approximately 40 minutes.   
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The next three visits will each last approximately two and a half hours. On 
each of these visits you will be asked to drink a carbohydrate drink.  Over the 
next three hours, small samples of blood will be taken via an indwelling 
venous cannula (i.e. from a small plastic tube positioned in an arm vein).  This 
is similar to a hospital visit but smaller samples of blood (6ml) will be taken.  
After this, we will ask you to undertake 20 mins of exercise on the cycle 
ergometer at up to 40% of your predicted maximal oxygen capability.  During 
this time, we will monitor whether your body is metabolising fat or 
carbohydrate by measuring your breathing. 
 
Between visits two and three, you will be given either L-carnitine L-tartrate or 
a placebo (a placebo is almost like a fake tablet but with no L-carnitine in it).  
You will not know which you are taking, as they will be randomly selected.  
Between visits three and four you will be given either L-carnitine L-tartrate or a 
placebo.  Again you will not be made aware of what you are taking until after 
you have completed the study.  You will be given instructions on how and 
when to take the supplements and we will follow this up with phone calls 
during this time to check that everything is fine. 
 
To standardise the trials you will be required to report to the sports centre at 
the same time of day for each visit.  You will be asked to produce a food diary 
and exercise diary during the time of the study, and we wish you to adhere to 
the same food intake and exercise for at least the three days before each 
visit. You must not eat in the morning of each visit.  This is known as an 
overnight fast and helps us standardise tests.  You should try to lead the 
same lifestyle as you did before the study, but avoid alcohol for at least two 
days before each visit. 
 
Will I experience any problems? 
It is very unlikely you will experience any problems.  During the predicted 
maximal exercise capacity test you may experience some discomfort if you 
are not used to exercising.  During the final three visits you may experience 
slight discomfort when we take the blood samples.  We will however, do our 
up most to keep discomfort to a minimum. 
 
If taking part in this research project harms you, there are no special 
compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have 
to pay for it.  Regardless of this, if you wish to complain, or have any concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, the University Ethics Committee panel will deal with 
these. 
 
What will I get out of the study? 
You may not gain any personal benefit from this study.  It is hoped though that 
the results of this study will lead to future research within the University of 
Stirling to possibly test new ways of tackling and preventing obesity / type 2 
diabetes. 
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You will gain some insight into current research in this area and the 
experimental methods used.  Your results will be strictly confidential but at the 
end of the study we will be very pleased to discuss the findings with you.   
 
It is unlikely you will lose weight in the 5 weeks you participate in this study as 
a direct result of particiapting.  However we will give you advice on nutrition, 
exercise, physical activity and weight loss if this is something you would like. 
 
 
Who has reviewed the study? 
The ethics committee in the Sport Studies department at Stirling University 
has approved the study. 
 
If you need more information, or have any problems at any time during the 
study, please do not hesitate to contact one of the investigators. 
 
Thank you for taking part in this study.    
 
Contact Information: 
Tommy Craig  
Department of Sports Studies, Gannochy Sports Centre, University of Stirling, 
FK9 4LA 
01786 466904 
thomas.craig@stir.ac.uk  
 
Dr Stuart Galloway  
Department of Sport Studies, Cottrell Building, University of Stirling, FK9 4LA 
01786 466494 
sdrg1@stir.ac.uk 
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APPENDIX B 
 
 
 
CONSENT FORM 
 
 
CONSENT BY PATIENT/VOLUNTEER TO PARTICIPATE IN: 
The effects of L-carnitine supplementation on response to glucose ingestion 
and on fat metabolism at rest and during exercise 
..........................................................................................................................................
............................................... 
 
Name of Patient/Volunteer:     
..................................................................................................................................... 
 
Name of Study:                         
..................................................................................................................................... 
 
Principal Investigator:             
..................................................................................................................................... 
 
 
I have read the patient/volunteer information sheet on the above study and have had the 
opportunity to discuss the details with ....Thomas Craig / Dr Stuart 
Galloway..................................................... 
and ask questions.  The principal investigator has explained to me the nature and 
purpose of the tests to be undertaken.  I understand fully what is proposed to be done. 
 
I have agreed to take part in the study as it has been outlined to me, but I understand 
that I am completely free to withdraw from the study or any part of the study at any 
time I wish. I understand and agree that my participation in the study is entirely at my 
own risk. 
 
I understand that these trials are part of a research project designed to promote medical 
or scientific knowledge, which has been approved by the Sports Studies Ethics 
Committee, and may be of no benefit to me personally.  The Sports Studies Ethics 
Committee may wish to inspect the data collected at any time as part of its monitoring 
activities. 
 
I also understand that my General Practitioner may be informed that I have taken part 
in this study if any unusual or surprising observations are made. 
 
I hereby fully and freely consent to participate in the study which has been fully 
explained to me. 
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Signature of Patient/Volunteer: 
..........................................................................................................
........ 
 
   Date: 
..........................................................................................................
........ 
 
I confirm that I have explained to the patient/volunteer named above, the nature and 
purpose of the tests to be undertaken. 
 
Signature of Investigator: 
.............................................................................................................
.............. 
 
 Date : 
......................................................................................................................
...... 
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APPENDIX C 
 
Date Physiologist Signature 
   
   
   
 
 
Pre-Participation Health Screen Questionnaire (PPHS-Q) 
 
PPHS-Q is an exercise – specific checklist for classification of training categories. 
Accuracy in completion of the PPHS-Q is of the utmost importance 
 
The purpose of the Fitness Centre (FC) pre-participation health screen is: 
 To optimise safety during exercise testing and programme description. 
 To identify medical risk factors which may contra-indicate exercise. 
 To identify those with special needs. 
 
 
Name:______________________________________Age:______________    FC no______________ 
Address_________________________________________________________ Gender:______________ 
______________________________________________Tel:_______________(H) ______________(W) 
Doctor’s name:__________________________________Tel:_______________(H)______________(W) 
 
                                                     Section A: Medical History  Summary and Recommendations 
Date:  
Date:  
Date:  
 
                                                            Section B: Coronary Heart Disease Risk Index Date Date Date 
              Group     
1. 1-10 No supervision required – exercise at will    
2. 10-17 No supervision required – use general exercise guidelines    
3. 18-27 No supervision required – use prescribed programme only    
4. 28-40 Use prescribed programme – Personal Training recommended    
5. 41+  Use prescribed programme – Personal Training and re-test within 8 weeks recommended    
 
                                                                               Section C: Physical Activity Index 
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 Date:    
Activity Level Times per week Risk level    
Inactive 0 occasional Very High    
Semi-active 1 High    
Active 2-3 Moderate    
Very active 4 or more Low    
 
SECTION A                                                              MEDICAL 
HISTORY 
 
Have you ever been told that you have had or have any of the following conditions? If yes, please mark with an X in the 
appropriate box: 
CARDIAC (Heart Related Diseases)   
 Heart Attack  High blood pressure 
 Coronary thrombosis (blood clot)  Rheumatic fever 
 Narrowing of arteries  Angina / Chest Pain 
 High cholesterol  Congenital Heart Disease  
    
 Further / comments   
  
PULMONARY (Lung Diseases)   
 Asthma  Exercise-induced asthma 
 Chronic Bronchitis  Emphysema 
 T.B.   
    
    
 Other / comments   
 
OTHER   
 Type I Diabetes (insulin dependent)  Type II Diabetes (non-insulin dependent) 
 Anaemia (ion deficiency)  Rheumatic fever 
 Kidney disease  Angina / Chest Pain 
 Rheumatoid Arthritis  Congenital Heart Disease  
   Pregnant  
 Other / comments   
 
ORTHOPAEDIC SURGERY (Musculo Skeletal)   
Surgery                    
 Neck  Hip 
 Back  Knee 
 Shoulder  Ankle 
 Arm  Foot  
 
 
 
Other / comments 
 
 
 
 
 
INJURY 
Have you suffered any of the following injuries? If so, how long ago? 
 Neck vertebrae  Back vertebrae 
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 Rotator cuff  Impingement Syndrome (shoulder) 
 Tennis elbow  Runner’s knee 
 ITB  Lower leg  
 Achillies Tendonitis  Plantar Fascitis  
 
 
 
Other / comments 
  
 
 
MEDICATION 
Do you use medication at present for any of the following? (If yes, please state the drug) 
 Heart rhythm  Blood pressure 
 Blood clotting.  Blood circulation 
 Asthma  Bronchitis 
 Emphysema  Flu 
 Diabetes  Thyoid dysfunction 
 Cholesterol  Anaemia 
 Kidney  Liver 
 Arthritis  Muscle injury 
 
 
 
Other / comments 
 
SECTION B                                                  CARDIOVASCULAR 
DISEASE RISK INDEX 
 
Please read the following questions carefully and answer each accurately. Mark your choice with an X. 
 
History of heart attack or bypass surgery / angioplasty 
0  None 5  1 – 2 years ago 
2  Over 5 years ago 8  < 1 year ago 
4  3 – 5 years ago    
 
 
Family history of heart disease 
1  No known history 
2  1 relative with cardiovascular disease over the age of 60 
3  2 relatives with cardiovascular disease over the age of 60  
4  1 relative with cardiovascular disease under the age of 60  
6  2 relatives with cardiovascular under the age of 60 
8  Heart – related sudden death: 
  Male, first degree relative before the age of 55 
  Female, first degree relative before the age of 65 
 
 
Age / Gender Index Smoking status 
0  Male / female under 30 years of age 0  None 
1  30 – 40 years of age 1  Pipe 
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2  Female 40 - 50 years of age 2  1 – 10 cigarettes daily 
3  Male 40 – 50 years of age 3  11 – 20 cigarettes daily  
3  Female 50 – 60 years of age 4  21 – 30 cigarettes daily 
4  Male 50 – 60 years of age 5  31 – 40 cigarettes daily 
4  Male / female 60+ years of age 6  41 – 60 cigarettes daily 
   8  + 60 cigarettes daily 
   State how long you have smoked for: 
Years______________months____________ 
 
 
How would you describe your bodyweight? Total Cholesterol  
0  Ideal weight 0  < 5 mmol / L 
2  0 – 5kg overweight  1  5.0 – 5.2 mmol / L 
4  6 – 10kg overweight 3  5.3 – 5.9 mmol / L 
6  11 – 15kg overweight 5  6.0 – 6.2 mmol / L 
8  + 15kg overweight 6  6.3 – 6.9 mmol / L 
10  Underweight 7  7.0 – 7.5 mmol / L 
   8  > 7.5 mmol / L 
     Not sure 
 
 
Systolic Blood Pressure Diastolic Blood Pressure 
0  < 130 mmHg 0  < 80 mmHg 
1  130 – 140 mmHg 1  81-90 mmHg 
2  141 – 150 mmHg 2  91 – 100 mmHg 
3  151- 160 mmHg 3  101 – 110 mmHg 
4  > 160 mmHg 4  > 110 mmHg 
  Not sure   Not sure 
 
 
Diabetes 
Occupational activity level 
0  None 1  Intense physical labour 
1  Type 11 (non-insulin dependent) 2  Moderate (walk often etc.) 
2  Type 1 (insulin dependent) 3  Sedentary 
 
 
 
 
 
 
Work Stress Tension 
0  No stress, very relaxed 
1  Moderate work stress and relaxed personality 
2  High work stress but cope well 
3  Very high work stress and tense personality 
4  Very high work stress, highly strung personality 
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Physical Activity Status (for a minimum of 30 minutes a session) 
1  Exercise 4 or more times per week 
2  Exercise 2 – 3 times per week 
3  Recreational sport once a week 
4  Recreational sport occasionally or complete lack of exercise 
 
 
SECTION C                                                          EXERCISE 
PARTICIPATION 
 
Do you participate in any of the activities more than twice weekly? 
(Please tick all relevant activities) 
 Jogging more than 5 km  Aerobic classes 45 min 
 Cycling more than 45 min.  Tennis 90 min 
 Swimming more than 600 m  Squash 45 min. 
 Gym (Combined strength / aerobic)  Team sport (outdoor) – rugby hockey, soccer 
 Gym (weights only)  Team sport (indoor) – basketball, netball, etc 
 Gym (aerobic only)  Canoeing / Rowing 45 min 
    
 
 
SECTION D 
 
I have read, understood and completed this questionnaire to the best of my knowledge. 
I am aware of the risk involved in fitness testing and understand the test procedures that I will perform. I give consent to 
participate in this assessment. 
 
TEST 1 
 
 Date:_________________________________ 
 
 
SIGNATURE:_______________________________________ 
 
 
WITNESS:____________________________ 
 
 
SIGNATURE OF PARENT:____________________________ 
(for a minor) 
 
TEST 2 
 
 Date:_________________________________ 
SIGNATURE:_______________________________________  
 
WITNESS:____________________________ 
SIGNATURE OF PARENT:____________________________ (for a minor) 
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TEST 3 
 
 Date:_________________________________ 
SIGNATURE:_______________________________________  
 
WITNESS:____________________________ 
SIGNATURE OF PARENT:____________________________ (for a minor) 
  
TEST 4 
 
 Date:_________________________________ 
SIGNATURE:_______________________________________  
 
WITNESS:____________________________ 
SIGNATURE OF PARENT:____________________________ (for a minor) 
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APPENDIX D 
L-Carnitine Study – Example of Exercise and Food Diary 
 
Please fill out all food intake a exercise and physical activity.  Example is given in the 
first box. 
 
Date: Example 
Exercise and Physical Activity 
 
8am:  walk from bus stop to office, 12pm:walk from office to canteen and back 
4.30pm: gym session, 15 mins cardio, 30 mins weights,  
5.30pm: 15 minutes in pool, walk to and from car 
8.00pm: general housework, playing with kids in front room 
 
Food Intake 
7am: 2 weetabix with sugar, tea with 2 sugar, banana 
10am; mars bar, can diet coke 
12pm: lunch, cheese baguette with mayo, walkers sensations, bottle diet fanta 
3.oopm: banana, tea 2 sugar digestive biscuit 
6.30pm: dinner, glass semi skimmed milk, mince and tatties, tea 2 sugar and 
chocholate buscuit. 
9pm: slice of toast and tea with 2 sugars 
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Date:  
Exercise and Physical Activity 
Food Intake 
 
Date:  
Exercise and Physical Activity 
Food Intake 
Date:  
Exercise and Physical Activity 
Food Intake 
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APPENDIX E 
 
 
 
Predicted VO2max Test Sheet 
 
Subject Name………………………….. Subject Id……………………… 
Test Number……… DOB………….. Height………  
Weight……….. Body Fat……… Precict HRmax…………………. 
 
 Stage TIME Workload Sample Result 
  
  
  
1 
1 min 50s   HR   
2 min 5s   BP   
2 min 35s   RPE   
2 min 50s   HR   
          
          
2 
  
  
  
4 min 50s   HR   
5 min 5s   BP   
5 min 35s   RPE   
5 min 50s   HR   
          
3 
  
  
  
7 min 50s   HR   
8 min 5s   BP   
8 min 35s   RPE   
8 min 50s   HR   
          
          
4 
  
  
  
10 min 50s   HR   
11min 5s   BP   
11 min 35s   RPE   
11 min 50s   HR   
 
 
Predicted VO2max………………… 40% VO2max…………………………... 
 
Test Carried out by……………………………… 
 
Date……………………………………………... 
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APPENDIX F 
 
Estimate 1
st
 Phase Insulin Release = 1.283 + 1.829 x INS30 – 138.7 x GLUC30 + 
3.772 X INS0 
 
Estimated 2
nd
 Phase Insulin Release= 287 + 0.4164 x INS30 – 26.07 x GLUC30 + 
0.9226 x INS30 
 
 
Stumvoll et al., 2000 
